annual report roche found digalen standardise heart medication roche present country continent alice keller manager roche japan female executive company massproduce vitamin rimifon treatment tuberculosis leap diagnostic cobas bio automate lab device roferona genetically engineer cancer therapeutic roche acquire pcr technology roche launch phelophepa mobile health clinic south africa protease inhibitor aids mabtherarituxan world target antibody cancer drug roche acquire boehringer mannheim alliance chugai pharmaceutical japan children walk global children charity integration biotech pioneer genentech cobas hpv test detect cervical cancer kadcyla antibodydrug conjugate herpositive breast cancer acquisition foundation medicine ocrevus monoclonal antibody multiple sclerosis acquisition flatiron health covid test year make difference live million day breakthrough medicine innovative diagnostic solution improve live countless people worldwide year legacy promise future year anniversary reason celebrate life celebration create new memory resonate year pausing reflect precious moment past celebrate history culture endure purpose guide roche year sustainable healthy future celebrate lifejoint interview andr hoffmann jrg duschmal roche stability longterm think andr hoffmann jrg duschmal member roche found family board director occasion year anniversary share thought past present future company ancestor fritz hoffmann found roche represent fourth fifth year ago milestone generation found family anniversary mean describe role family hoffmann feel extremely proud great company structure grandfather fritz hoffmann hoffmann longterm family ownership family member pleased help provide stability company roche evolve year anniversary establish active partnership management important milestone company board company longterm success think sustainably longterm exist forever think structure triangle unite family board director duschmal look rich history corporate executive committee corporate year able shape chapter executive committee lead company roche new member board director board director set strategy monitor course great privilege implementation owner ensure look forward roche longterm direction separation control play important life execution important role family representative privilege mean exactly major responsibility duschmal early childhood roche present life feel duschmal fact family strongly connect teach success story roche last bond family beginning fill pride roche continue company correspond responsibility count rely commit loyal grow basel roche course majority shareholder want pass healthy visually present city sustainable company generation think longterm vision andr grew camargue france bring company able boldly roche play big role invest area pay upbringing year certainly big advantage hoffmann bit different stable family ownership bring remember father speak proudly roche grow switzerland way family constant connection company involve decisionmake start realise actual importance hoffmann family engage impact company teenage year selection member board director governance company sustainability alongside important value goal business activity like marketing sale company represent individual truly sustainable action board pay attention engage define term durability selection process traditionally success define positive cash flow simple measure family deal internal financial consequence business activity fail difference affect important forward measure social human environmental look business decision impact action use hoffmann wellbee natural social human capital way company common driver create sustainable longterm value start share value joint responsibility constantly act eye great keep family value impact society connect bring stability year roche thinking tomorrow history legacy equally important duschmal family priority future listen focus important thing longterm success jrg perspective sustainability roche help find common ground duschmal agree andrs point andr say benefit company additionally scientist associate sustainability roche strength innovation powerhouse core roche success order successful long term duschmal roche manage reinvent innovate frontier scientific original idea knowledge benefit patient produce medicine high quality matter take certain risk today today roche large biotech appear lucrative short term create diagnostic company world owe sustainable value long term success innovative research partnership enter researcher roche foresight courage continue time future duschmal wonderful time experience eyeopener importance hoffmann success team science great thing achieve great talent world contribute able experience firsthand everyday sustainable culture value company mean everyday way keep societal patient need work great personal commitment focus perseverance take advance research idea therapy save live talk sustainable way know sustainability ambassador andr make roche culture special believe important hoffmann special people topic roche interact hoffmann start let state drive passion difference obvious future sustainable patient shape future humanity continue thrive external partnership coincidence think behave sustainably partner choice manyjoint interview andr hoffmann jrg duschmal roche duschmal convince hoffmann position experience roche value live family invest day addition company commitment company long term asset essentially employee know follow science consist roche share give shape proud privilege responsibilitie ownership company ownership passive role active commit look future roche success real way alongside roche year employee work roche duschmal expect focus feel like investor prevention personalise prepare company therapy likely great generation advance therapeutic area great medical need neurological disease duschmal similarly future think industry collaboration share opportunity influence healthcare stakeholder succeed company value share package improve access healthcare believe relevant sell well availability datum positively commit longterm success change research impactful roche hoffmann hopefully roche company headquarter successful today task basel discuss move hand healthy company location generation family hoffmann active country today root success mean switzerland happy basel hoffmann roche create well location research future million people greatest conduct end success drive medical innovation open new innovation centre stateoftheart require bold risk require lab facility look forward visit room manoeuvre finished profit invest sustainably focus profit maximisation duschmal research basel right society value profit great network partner support generating activity delight witness long headquarters location support everyday act generosity kindness bring breakthrough innovation patient lead invoice send act right place graciously altruistic way thing make human let try theme roche year anniversary forget kind thinking celebrate life celebrate life continue sustainable organisation duschmal probably enjoy nice dinner year come family friend wealthy hoffmann celebrate life successful family significance harmony nature wish usour purpose roche patient need believe urgent deliver medical solution right develop innovation future passionate transform patient live courageous decision action believe good business mean well world come work day commit scientific rigour unassailable ethic access medical innovation today build well tomorrow proud work function company world rochecontent roche content shareholder letter report strategy diagnostic pharmaceutical personalise healthcare access healthcare people culture environment community engagement business ethic business performance corporate governance remuneration report arrochecomshareholder letter roche shareholder letterschairman shareholder letter roche dear shareholder found year ago roche milestone company history worked improve health life countless include early adoption biotechnology people world anniversary time believe year exception discovery monoclonal antibodie revolutionise employee partner develop cancer therapy pcr technology manufacture provide global access pioneer molecular diagnostic stateoftheart diagnostic treatment disease include covid roche innovation effort guide pioneer spirit identify seize opportunity characterise roche found remain future digitalisation sincere thank substantially increase pace company transformation chairman covid pandemic dominate world board director view health datum event past year medical practice opportunity pursue time know unknown pathogen ongoing development personalise suddenly spread present effective medicine time major challenge certainly analysis datum support laboratory roche establish effect research development new clinical trial pandemic fritz hoffmann take concept enable accelerate approval position merchant hamburg summer procedure innovative therapy cholera break result available patient fast experience decide set industrial pharmaceutical company return basel go forward want use digitalisation aim provide large quantity effective achieve medical progress low cost medicine uniform quality increase investment revolutionary concept time research development expenditure billion swiss franc year establishment year exceed roche repeatedly find courage healthcare company worldwide reinvent guide scientific progress recently remind visit poland roche particular strength long roche open branch early term mindset privilege great deal century impact researcher stability afford found leo sternbach polish chemist enormous family like express discover benzodiazepine valium sincere thank thinking sustainably librium indispensable dna delight motivated treatment anxiety insomnia nervousness select dow jones roche actively involve field sustainability indice world neuroscience ocrevus treatment sustainable company healthcare sector multiple sclerosis soughtafter receive recognition medicinal product thirteenth year state growth rate report constant exchange rate cer average year achieve additional milestone behalf board director wish extraordinary general meeting end thank sincerely valuable contribution november approve buyback roche success roche bearer share hold novartis past year nearunanimous vote confident delight propose jemilah mahmood billion swiss franc transaction doctor malaysia new member well strategic financial interest roche board director great expertise investor restore control field public health especially develop strategic decision require restrict region world particular experience operative scope enable help roche medicine diagnostic product accessible strong product pipeline severin schwan people world describe detail letter financial figure group sale rise roche special focus sciencedriven billion swiss franc net income amount innovation commit sustainability root billion swiss franc confirm roche switzerland open world right path light good performance board director propose dividend like thank shareholder increase swiss franc share non confidence loyalty voting equity security subject approval consecutive dividend increase finally like draw attention number change roche board director year member board director paul bulcke decide stand christoph franz reelection general meeting chairman roche board director december julie brown bernard poussot jrg duschmal representative shareholder group pool voting right christoph franz chairman prof hans clevers andr hoffmann vicechairman representative corporate governance sustainability committee shareholder group pool voting right audit committee severin schwan remuneration committee claudia suessmuth dyckerhoff chairmansnomination committee patrick frost nonexecutive director paul bulcke executive director anita hauser independent member board directors prof richard lifton committee chairpersonboard director roche shareholder letter ceo roche group roche dear shareholder improve people live deliver medical demand effective treatment innovation roche extremely high nervous system disorder year medicine recent study datum highlight benefit develop decade ago greatly benefit ocrevus multiple sclerosis enspryng million people today world health nmosd rare disease affect central organization model list essential medicine nervous system roche researching include product record high develop dozen medicine treat neurological disorder include huntington future roche success base parkinson alzheimer disease medical innovation despite success great need well therapy diagnostic worldleade portfolio area cancer dementia diagnostic solution covid infection far covid need work tirelessly start pandemic effective treatment people constantly expand range coronavirus disease well life cure need test roche invest significant amount precision diagnostic find cause establish additional production capacity disease treat early possible meet continue high demand routine stage preventive diagnostic gain diagnostic increase significance innovative diagnostic essential prevention look ahead please continue early detection treatment decision infectious high demand newly launch medicine disease cancer condition diagnostic test development product pipeline division expand lead position area infectious disease year continue significant target acquisition tib molbiol bring progress patient tecentriq substantial number test broad portfolio cancer immunotherapy people earlystage molecular diagnostic solution acquisition lung cancer approve mean genmark strengthen commitment hope cure polivy medicine combat antibiotic resistance launch year significantly improve outcome molecular pcr diagnostic test panel form aggressive blood cancer simultaneously detect common respiratory pathogen patient sample ophthalmology grant regulatory approval susvimo innovative eye implant accurate diagnosis enable patient receive susvimo offer alternative monthly injection appropriate treatment prevent eye life people expose antibiotic wet agerelate macular degeneration great respond diagnostic test play deal easier furthermore apply regulatory crucial role combat infectious approval vabysmo new class disease help prevent disease eye medicine target key signal cervical cancer hepatitis crelate pathway cause retinal disease liver cancer digitalisation area roche invest digital product specific app heavily significant deliver well support monitoring factor medical progress roche embark treatment therapeutic area strategic partnership foundation medicine neurology ophthalmology fmi flatiron health year ago recognise combine highquality genomic achieve realworld data patient datum clinical possible people work practice deliver completely new approach roche worldwide like thank data set available sufficient quantity exemplary dedication commitment quality represent enormous potential despite challenge pandemic go forward grasp today people research development production crucial driver effort advance distribution support function personalise healthcare focus world work tirelessly ensure patient make significant improvement cancer continue receive lifesave medicine patient accelerate discovery diagnostic development new cancer medicine like thank shareholder treat cancer effectively necessary trust place company understand molecular mechanism underlie disease autumn roche partner fmi launch genome profiling kit personalise cancer research kit enable researcher use fmis comprehensive genomic profiling assay laboratory digital solution enable recording structuring analyse patient datum support clinical severin schwan decisionmake drive forward research ceo roche group roche corporate executive committee december alan hippe chief financial information officer claudia bckstiegel general counsel aviv regev head genentech research early development gre william pao head roche pharma research early development pre severin schwan ceo roche group cristina wilbur chief people officer bill anderson ceo roche pharmaceutical barbara schdler head group communications james sabry global head pharma partner thomas schinecker ceo roche diagnostic member enlarge corporate executive committeecorporate executive committee roche reporting strategy roche reporting strategy report approach roche commit transparent reporting endeavour drive economic social environmental performance diligence financial performance report scope boundary risk advisory team overall process financial nonfinancial reporting consist review audit committee board annual report finance report director review externally appropriate online report contain annual financial risk management embed level statement consolidated financial statement roche group pharmaceutical diagnostic nonfinancial performance indicator cover division global function conduct formal region division roche group risk opportunity assessment process january december financial year develop response plan report scope define outlined material risk opportunitie finance report significant change scope compare read corporate governance gri standard materiality identify longterm business sustainability follow gri global reporting trend associate risk opportunity initiative guideline transition annual basis integrate gri standard gri exist group risk management process guideline disclose critical impact year emerge trend include associate risk activity environment society opportunity identify internal economy respect conduct external source materiality analysis corporate level conduct base finding sustainability steer second global materiality assessment include committee prioritise select business expert interview feedback sustainability trend identify trend stakeholder result assessment healthcare evolution societal crisis feature page report publish website link sustainable development goal support united nations sustainable development goal sdgs sphere risk management corporate business strategy contribute risk management policy set roche number sdgs particularly approach identify analyse manage pleased dedicated goal health sdg report internal external risk goal closely connect achievement opportunity consolidated group risk report universal health coverage go hand cover material risk opportunity hand well access quality essential discuss annually corporate executive medicine diagnostic fit perfectly material topic committee review board director vision improve save life personalise healthcare effectiveness group risk management sdgs integral process regularly monitor group annual reporting report arrochecom rochecomarepdf rochecomfbepdf risk management rochecomriskmanagement key performance indicator rochecomperformanceour reporting approach roche example contribution goal list sdg webpage link business sustainability trend map material topic feature healthcare evolution signatory global compact ungc healthcare move continuum care approach include commit integrate universal principle prevention treatment cure offer wide range product area human right labour environment service solution unique opportunity accelerate delivery anticorruption business strategy truly integrate patientcentric personalise healthcare solution culture daily operation report example introduce navify symptom tracker result achieve year publish offer remote monitor covid symptom develop communication progress quarter cloudenable integration engine support digital health ecosystem mobile app patient healthcare professional like mysugr app monitor manage diabete smartphone risk external assurance opportunity associate new digital health arena nonfinancial reporting verify assess manage group risk management process pricewaterhousecoopers pwc independent party focus materiality determination societal crisis process design sustainability risk ineffective social model limit economic educational opportunity determination process prospect likely lead dissolution societal solidarity figure area safety security health exacerbate mental health deterioration youth disillusionment environmental protection people contribution consider role drive publicprivate partnership result roche strengthen initiative working collaboration government healthcare control framework review procedure provider tackle risk opportunity demonstrate report aspect figure relate employer choice acknowledge importance grant donation sponsorship healthcare health wellbee employee provide offering patient organisation subject support employee family flexible working arrangement reasonable assurance perform pwc parental leave man woman childcare facility figure disclose nonfinancial reporting provision help employee combine career family role key performance indicator webpage include unpaidleave option people need care elderly relative pwc assurance report independent assurance report materiality impact purpose patient need identify meet need day sustainable succeed sustainability build business strategy everyone job roche approach holistic integrate aim reduce dimension sustainability greenhouse gas emission absolute zero society contribute well partnering supplier reduce tomorrow emission mutual benefit environment minimise impact nature economy economy invest medical advance business meet need patient create job ensure livelihood continue create quality job provide people family secure livelihood mean roche earn competitive return investor day promote innovation translate science pioneer medicine society diagnostic help patient live long contribute well society enable well productive life enable right treatment right patient right support contribute time right value develop local economy new medicine way diagnose disease gain insight datum commitment describe strategy setup design expand access innovation help innovation autonomous research patient live long well live development centre alliance come deep respect human external partner foster diversity scientific right reach especially patient approach agility roche operate business partner supplier local community country local team implement course colleague world strategy measure performance emphasise employee safety health report stakeholder progress development promote diversity goal set inclusion integrity mutual respect equal opportunity materiality assessment stakeholder engagement environment engage stakeholder essential respect healthy planet build trust understand environment priority expectation embed feedback found family company strategy daily business able committed halve environmental jointly address common issue develop impact operation product longterm solution sustainability rochecomsustainability materiality rochecommateriality stakeholder engagement rochecomstakeholderengagement key performance indicator rochecomperformance contribution sdgs rochecomunsdgsmateriality impact roche order identify topic particularly relevant roche stakeholder society large deliver last share value conduct indepth materiality assessment society environment corporate level key stakeholder approach materiality sustainability assessment integrate building group risk management process inclusive design collaboratively colleague multiple function gather insight broad range internal external stakeholder economy identify important press issue roche address year identify material topic cluster main category stand highly relevant key stakeholder properly address topic align current goal measure performance define set indicator impact impact performance material topic support sdgs society million patient treat access healthcare contribute roche medicine digitalisation well tomorrow billion test conduct science innovation roche diagnostic product product quality safety new molecular entity ethic compliance clinical development employee engagement woman executive position woman management employee engagement score environment decrease environmental energy efficiency minimise impact employee impact nature electricity come sustainable source decrease greenhouse gas emission economy sale invest longterm mindset invest medical advance employee create job ensure livelihood cluster material topic detail rochecommateriality strategy focus find new medicine diagnostic establish database insight evolve practice medicine help patient live long well live business environment undergo tremendous seamless patient journey continue change face new challenge concentrate energy prescription medicine complexity care increase pressure vitro diagnostic increasingly data healthcare budget time new insight diversify sector opportunity arise major advance life like generic biosimilar overthecounter sciences digitalisation healthcare medicine turbulent time guide delivery create value common purpose patient stakeholder partner choice bring need company bring significant medical benefit patient doctor novel diagnostic treatment patient payer offer great place work year patient remain core employee deliver sustainable positive reason come contribution society earn competitive work day return investor focus vision fitting treatment ultimately deliver commitment take patient provide right therapy right people integrity courage passion patient ensure good response right make difference patient people time right value approach combine proud roche rich expertise pharmaceutical diagnostic expand datum science capability drive leadership inspire outcome matter effective efficient research enable embrace diversity inclusion different well therapeutic decision patient background perspective experience entire organisation foster innovative solution pursuit excellence science rest benefit patient way work key element exceptionally broad deep enable agile networked response understand disease biology seamless increase pace change balancing need integration capability pharmaceutical stability speed flexibility diagnostic diversity approach maximise innovation longterm orientation setup design innovation autonomous research development centre work partnership party alliance external partner offer integrate solution improve medical foster diversity scientific approach health economic benefit work agility global geographical scale reach different stakeholder healthcare enable attract talent lead global ecosystem broaden access offering science cluster quickly bring solution people need ultimately provide people need themour strategy roche focus leadership fitting treatment patient inspire outcome matter distinctiveness way work excellence science agile network delivery setup value stakeholder build innovationdiagnostic roche diagnosticsdiagnostic roche diagnostic solution backbone treatment decision cancer infectious disease health threat quest well solution healthcare great challenge depend diagnostic covid pandemic profoundly raise quarter introduce awareness role diagnostic play disease sarscov antigen self test nasal prevention management covid selfadministered testing home test continue dominate healthcare landscape enable patient gather sample pandemic remain global threat area nose nasopharynx country vary degree progress identify infectious sarscov contain virus end minute initially grant special approval million confirm case european country test receive covid million death mark june expand availability country accept mark spread virus place enormous strain health system heighten need supplement covid portfolio million test roche proud june launch sarscov assay industryleade portfolio covid solution cobas liat system make minute remain committed develop pointofcare poc pcr test receive emergency bring market additional test solution use authorization asymptomatic strengthen global fight disease screening test detect currently know sarscov variant bring fast pcr testing march launch cobas nearpatient setting like clinician office sarscov set variant test run emergency room urgent care clinic cobas system develop detect differentiate sarscov mutation know december receive fda emergency use variant researchuseonly test help authorization covid athome test scientist track mutation prevalence assess use simple anterior nasal swab sample spread circulate variant monitor convenient selfcollection selfteste potential impact treatment vaccine public individual aged year old adult health measure test preoptimise assay child aged year old produce design readytouse test cassette predefine accurate reliable quick result software parameter reduce testing minute sarscov know variant complexity shorten turnaround time concern include omicron navify pass enable individual receive health credential easily seamlessly mobile device month add additional researchuseonly ruo test kit detection mutation present novel omicron sarscov variant virsnip sar spike insepe ruo virsnip sarscov spike ruo virsnip sar spike ruo kit develop tib molbiol newly acquire subsidiary virsnip variant kit allow differentiation range unique mutation present omicron variant compare sarscov variant use lightcycler cobas analyser technology call quantitative polymerase chain reaction qpcr help researcher improve variant detection viral research address range unique mutation omicron variant novel assay launch navify pass digital solution allow people year milestone receive covidrelated health datum mobile app available country revolutionise diagnostic include united kingdom netherlands polymerase chain reaction pcr trust way create unlimited solution facilitate access copy dna original strand copy dna event travel enable return normality reliably wide variety test diagnose monitor disease basic molecular biology research pointofcare testing play essential increasingly important role healthcare kary mullis scientist cetus corporation conceive pcr deliver high medical value solution method copy dna synthesise large amount specific target diagnostic information patient healthcare dna year team cetus scientist recognise professional need potential impact pcr molecular biology research roche pointofcare strategy focus refine theoretical process reality infectious disease like covid influenza sepsis test disease roche buy right pcr cetus invest currently development refining science use molecular diagnostic detect disease roche molecular diagnostic define refined pcr remain clear leader trailblazer technologydiagnostic roche diagnostic covid unfortunately pandemic people oesophageal cancer mutation present disease face delay treatment half solid tumour cancer common disease monitoring achieve good genetic change identify far human cancer possible result patient depend heavily test especially impactful oesophageal early diagnosis rapid access therapy cancer sixth common cause cancer meet covid testing need death worldwide particularly difficult significantly increase installation treat sign symptom highthroughput system cobas early stage instal result hour laboratory world support phc approach perform million test cancer care receive fda approval october pandemic health system use ventana pdl assay additional capacity screen diagnosis companion diagnostic identify patient treatment monitoring area cancer nonsmall cell lung cancer eligible treatment cardiovascular disease women health tecentriq immunotherapy approval base result phase iii spite pressure meet ongoing impower study expand industryleade demand covid test launch portfolio companion diagnostic test solution health condition condition launch elecsys growth differentiation tremendous stress strain patient factor gdf immunoassay detect love one healthcare system specific form weight loss know cachexia patient solid tumour test oncology add important new test receive fda breakthrough device designation aid fight cancer march helps determine eligibility treatment target expand label ventana alk highly prevalent complication cancer assay identify alkpositive lung cancer patient eligible target treatment ventana mmr rxdx panel launch april lorbrena lorlatinib pfizer assay fdaapprove companion diagnostic immunohistochemistry test approve fda identify patient advance recur companion diagnostic lorbrena test endometrial cancer well suit previously approve companion treatment gsk immunotherapy drug jemperli diagnostic target treatment dostarlimabgxly endometrial cancer include xalkori crizotinib pfizer zykadia ceritinib common gynaecologic cancer novartis roche alecensa alectinib woman globally die endometrial cancer label expansion advance roche commitment year currently limited treatment option personalise healthcare phc provide lung exist woman disease progress cancer patient access treatment firstline therapy companion option well chance progressionfree diagnostic identify endometrial cancer patient survival compare standard care eligible antipd immunotherapy test fda approve august help determine month later launch elecsys antip base cancer biomarker patient immunoassay help diagnose bowel breast solid tumour benefit jemperli system test software solution help laboratory improve efficiency quality control information sharing support physician patient treatment decision woman increase risk highgrade cervical precancer require immediate diagnostic procedure woman need repeat testing routine screening improve cvd management cardiovascular disease cvd remain lead cause death globally claim live nearly million people year covid pandemic management disease challenge especially patient unaware disease reluctant seek care experience classic symptom like chest pain biomarker play critical role improve diagnosis management heart attack heart failure april announce additional testing capability key biomarker highsensitive cardiac troponin ctnth nterminal probrain natriuretic peptide ntprobnp heart failure affect million people october announce impact improve worldwide place great stress patient primary screening colposcopy triage clinical caregiver healthcare system despite trial datum show clear benefit treatment hospitalisation outlook poor cintec plus cytology test woman new elecsys ntprobnp test extension high risk develop cervical cancer identify patient type diabetes woman diagnose cervical cancer great risk develop heart failure year approximately die helps identify patient risk develop atrial preventable cancer cause infection fibrillation abnormal heart rhythm highrisk type human papillomavirus hpv lead stroke brain damage death new result trial woman extension elecsys ctnth testing help predict aged year publish heart attack risk mortality noncardiac international journal cancer surgery patient assess longterm cardiovascular event risk asymptomatic patient study woman positive high risk hpv receive followup triage test help infectious disease threat covid determine cervical cell transform covid retain world attention cervical precancer biomarkerbase range infectious disease affect million cintec plus cytology test show significantly people rank cause high sensitivity detect cervical precancer death worldwide continue develop test compare pap cytology roche test aid solution infectious disease clinician confidently determine covid fact sheet cardiovascular disease world health organizationdiagnostic roche march launch elecsys epsteinbarr identify multiple pathogen overlap virus ebv immunoassay panel improve ebv symptom test panel run staging country accept mark cobas omni utility channel highvolume infect world population cobas system new adulthood ebv normally remain dormant molecular diagnostic panel use single patient threaten sample test influenza influenza weaken immune system transplant respiratory syncytial virus rsv patient panel include immunoassay adenovirus adv human metapneumovirus detect specific ebv antibodie elecsys igm hmpv enterovirusrhinovirus evrv elecsys ebv vca igg elecsys ebna igg parainfluenza test panel help clinician fast decision run compare treatment transplant patient conventional diagnostic method flexible rule acute infection syndromic panel reduce unnecessary testing undetecte hiv provide important insight clinician quickly test newly approve claim extension combine covid testing elecsys brahms procalcitonin pct immunoassay cobas systems monitor patient antibiotic therapy million patient year aid patient respiratory infection identify resistance enable target sign symptom specific antibiotic use detect severe bacterial discern root cause illness infection million patient year late set syndromic respiratory solution early therapeutic intervention allow clinician choose appropriate test base healthcare set seasonal completion genmark diagnostic outbreak patient need testing acquisition strengthen broaden medically relevant necessary enable infectious disease portfolio take targeted therapy avoid misuse antibiotic major step syndromic panel testing reduce unnecessary intervention know multiplex testing detect common pathogen cause disease acquisition tib molbiol group single rapid test single patient sample december able expand clinician prescribe right therapeutic portfolio ceivd assay hour day compare research use assay lightcycl conventional testing algorithm roche pcr systems magna pure sample preparation genmark benefit patient laboratorie system successfully partner healthcare provider combine tib molbiol year expertise portfolio collaboration instrumental create sarscov detection test january acute respiratory infection include mere day novel virus complication infection sarscov sequence world lead cause death disability september launch respiratory test panel market help transform healthcare digitalisation advanced technology billion test conduct pathology algorithm upath upath roche product include upath image analysis billion test diagnose sarscov infection breast cancer important measure relate antibody addition biomarker complete digital pathology include million test health condition breast panel image analysis algorithm time thousand datum point individual patient create journey early detection liver cancer specifically help identify change health hepatocellular carcinoma hcc mark enable track similar patient cohort grant november elecsys gaad institutions geographie eventually algorithmic score combine gender age allow comparison outcome roche elecsys afp elecsys pivkaii assays predictive measure artificial intelligence liver cancer cancer machine learning rise responsible death year detect manage early goal improve patient care patient fiveyear survival rate increase expand access innovative image analysis algorithmic score help aid diagnosis launch digital pathology open environment patient chronic liver disease open environment roche building hepatitis cirrhosis followedup open application programming interface api mri scanning provide clinician framework enable thirdparty company accurate information support treatment deploy algorithm navify digital decision help increase access liver pathology cloud version roche upath cancer testing enterprise software addition digital pathology open environment announce digitalisation pointofcare set october collaboration pathai ibex cobas pulse system represent major advance medical analytic aibase digital pathology revolutionary new glucose management application solution professional blood glucose meter androidbase operating system grow involvement underscore load industryleade medical app belief hold significant promise advance perform essential function nurse doctor pathology imaging benefit cancer lab manager cobas pulse launch patient precise diagnosis november believe system serve turn help clinician identify targeted treatment gateway future digital health service lead well result medical practice breast cancer announce january improve lab management improve ceivd launch automate digital pathology patient outcome algorithm upath image analysis innovative test digital insight enhance upath dual ish image analysis laboratory management solution transform help determine good treatment strategy healthcare improve outcome new patient december launch digital era come great opportunity benefit new researchuseonly ruo automate digital patient laboratory world bydiagnostic roche digitalisation healthcare continually improve ability collect curate sense vast quantity diverse patient datum identify develop innovative predictive diagnostic testing enable early detection treatment significantly improve outcome addition help increase number case review pathologist reduce human error improve accuracy enable personalise treatment plan quarter launch update expand lab analytical application customer include viewic labop molecular newly expand offering provide insight entire menu roche cobas system datum directly uploaded analytic roche viewic labops core approve launch region world enhance digital diagnostic portfolio application provide laboratory hospital personnel easy way track review identify operational trend challenge visibility guide decisionmake process optimise operation customer delivery overall lab performance target efficient manner labops core provide set turnkey analytic enable datum drive decision improve operational effectiveness clinical laboratory launch new diagnostic platform cobas pure cobas pro high throughput cobas new system enhance offering enable comparable result lab different size serum work area space core laboratory molecular lab roche goal provide patientcentric continuity care stage patient journey prevention diagnosis treatment monitoring aftercare diabete care diabetes management complex personal handset algorithm analyse datum real time achieve therapy goal ongoing challenge decide stop insulin delivery adjust believe personalise tailor basal rate deliver automatic correction therapy well outcome bolus need continue implement solution leverage integrate personalised diabetes management april mysugr acquire roche approach announce integration novo nordisk novopen novopen echo plus mysugr april diabetes care begin offer app logbook ios integration follow accuchek insight insulin pump pair collaboration agreement sign roche diabeloop hybrid closedloop system novo nordisk user record scope previously announce partnership insulin data mysugr app track combine people living diabete germany italy spain blood glucose value activity meal switzerland netherland able relevant diabetes datum solution use accuchek insight insulin pump currently available sweden denmark diabeloop dblg system feature pilot project select healthcare selflearning algorithm host dedicated institution germany austria mysugr app integral diabetes care open ecosystem offer feature like mysugr app fully integrate rochediabete structure documentation datum accurate insulin care platform dose calculation reminder coach help people well manage daily diabete routine fully integrate rochediabete care platform enable healthcare professional comprehensive overview relevant patient datum feature remote patient monitoring important people diabetes spend significantly time physician covid pandemic sign collaboration agreement eli lilly company integrate datum company connect insulin pen solution roche open ecosystem mysugr app pair mysugr app tempo smart button automatically transfer datum bluetooth technology mysugr logbook roche open diabetes management ecosystemdiagnostic roche test result produce system billion cobas system instal active inlicense agreement active outlicensing agreement diagnostic fact covid test enable month million new assay panel algorithm oncology diabetes care diagnostic test solution currently covid portfolio new launch digital decision support new assay claim extension laboratory insight solution solution infectious cardiovascular disease diagnostic roche lung cancer patient go cure amanda nerstad mom alkpositive lung cancer share story importance biomarker testing raise money cure jog hill tennessee home lemonade cure united states amanda find gasp neighbourhood lemonade stand inspire breath friend diagnose daughter incredible support pneumonia young mom wonder family friend nerstad family raise usd lung cancer research project help fund trip doctor day launch alk vaccine study hope turn harrowing journey day amanda non terminal disease chronic illness go smoker diligent health fitness cure amanda say alkpositive diagnose stage lung cancer tell lung cancer give platform raise money little week live amanda research cure think daughter isabella greta note lunchboxe morning drive change negative bias great day mommy love think lung cancer patient want go write note devastating know lung cancer ask breast cancer get search clue drive amandas question ask cancer oncologist order test smoke important know nervously wait result biomarker test lung lung cancer nerstad find powerful hope amanda dedicate inspire researcher welcome news industry leader include roche amanda test positive change celebrate year anniversary drive anaplastic lymphoma kinase alk gene innovation hope year roche find percent nonsmall cell lung help research forward annual cancer case candidate target cancer testing available treatment specifically people test positive hopefully catch cancer early say mutation month treatment leave amanda exhaust ill doctor surround positivity suggest new alktargeted therapy today amanda find joy make difference celebrate complete metabolic response cancer warrior sweet moment wrap evidence disease effect love family determine aspect life time important amanda mission spread word live enjoy moment importance biomarker testing share lovely laughter dinner experience survivor young mom table snuggle couch favourite like fundraise alk positive movie surround positivity nonprofit organisation raise embrace day amanda say usd million alkpositive lung cancer research go curepharmaceutical roche pharmaceuticalspharmaceutical roche drive patient benefit burden poor health increase grow population high life expectancie increase chronic disease continue discrepancy access healthcare mean demand healthcare continue grow system struggle industry society need pharmaceutical investigational rethink innovate provide antiviral medicine covid care sustainable way milestone covid portfolio roche long history develop ronapreve deliver breakthrough medicine march new phase iii datum show meaningful difference life million ronapreve reduce hospitalisation death people worldwide today world nonhospitalise patient covid make april phase iii prevention trial show fundamental change way operate subcutaneous administration ronapreve work stakeholder partner reduce risk symptomatic covid leverage development science infection technology deliver matter june university oxford announce patient benefit far cost society preliminary phase iii result recovery study patient hospitalise time bold new approach need covid result show ronapreve go bring reduce risk death solution mount natural antibody response seronegative effort pandemic join july japan country approve force patient society ronapreve treatment mild moderate covid spur rethink partner covid follow approval treatment develop diagnostic treatment option prevention november work speed september phase iiiii trial datum show imagine goal deliver innovation ronapreve significantly reduce viral load patient seven day treatment patient hospitalise covid building partner effort september recommend use continue work gilead science ronapreve nonsevere covid patient combination study evaluate medicine high risk severe disease roche actemraroactemra gilead veklury patient severe critical infection hospitalise patient severe covid seronegative status associate pneumonia further october ronapreve actemra work regeneron antibody cocktail roactemra include casirivimab imdevimab ronapreve commission portfolio promising story work atea covid treatment pandemic production logistic team demonstrate deep commitment serve patient worldwide july issue new treatment guideline covid recommend interleukin receptor blocker actemra roactemra patient hospitalise severe critical covid december european commission extend marketing authorisation actemraroactemra include treatment covid adult receive systemic corticosteroid require supplemental oxygen mechanical ventilation decision come hour recommendation european medicine agencys committee medicinal product human use reflect urgent need medicine tackle covid pandemic june atea pharmaceutical announce interim result phase ata trial hospitalise patient moderate covid high risk poor outcome november new sarscov variant interim result indicate rapid sustain omicron classified variant antiviral activity sarscov patient concern analysis show hospitalise setting ronapreve retain neutralise october atea pharmaceutical announce activity omicron variant ronapreve result phase moonsong study retain activity main nonhospitalise patient variant concern include delta activity mild moderate covid study ronapreve potential future variant meet primary endpoint show continually assess significant reduction viral load baseline compare placebo overall study actemraroactemra population june roches actemraroactemra receive november roche atea pharmaceutical fda emergency use authorization communicate roche decide end treatment covid hospitalise adult partnership atea programme child focus effort covid activitiespharmaceutical roche pharmaceutical clinical pipeline phase phase phase iii registration oncology inflammationimmunology neuroscience infectious disease ophthalmology metabolic pipeline new molecular entity cover broad range disease highly innovative technology apply create produce active molecule advance clinical trial clinical trial essential medical progress study comprise european population datum trial help scientist clinician little representation community understand investigational medicine affect noneuropean descent difficult different group people specific genetic understand diverse genetic variant play marker disease support development role progression disease target personalise treatment closing gap real world demographic accurately makeup clinical matter trial represent realworld demographic past year focus robust datum ultimately effort closing gap clinical trial effective medicine patient ensure accurate representation patient need population world result research collaboration genentech deeply commit addressing barrier stanford university know trial pathfinder clinical trial participation widen access publish scientific journal nature expand innovative diagnostic study highlight realworld data therapeutic solution diversify genetic artificial intelligence help datum advance inclusive research globally address underrepresentation clinical research nonsmall cell lung cancer nsclc miss opportunity industry global clinical recent study majority nsclc trial participant european ancestry patient meet criterion participate represent global population clinical trial restrictive inclusion criterion additionally genomic data trial fail complete recruitment available european ancestry leave targeted time trial pathfinder show significant datum undiscovere datadriven approach eliminate restrictive eligibility criterion increase gap mean trial result total number eligible patient applicable patient population miss twice include enormous valuable data woman africanamerican study consider instance broad range age compromise black woman mortality rate study outcome breast cancer approximately great caucasian woman represent pandemic disproportionately woman trial study disease devastatingly impact people colour initiate clinical trial investigational determine treatment work good medicine covid pneumonia global patient require great deal clinical trial site enrol highrisk minority genomic datum currently data available public population include order enhance total gwas participant diversity genomewide association study gwa diversity monitor cancer fact figure african americans american cancer society enrollment racialethnic minority patient ovarian breast cancer trial fda analysis journal clinical oncology evaluate eligibility criterion oncology trial realworld datum naturepharmaceutical roche deeply commit address barrier clinical trial participation patient population world understand clinical profile actemra roactemra patient allow access underserved minority population commonly represent clinical trial approximately participant represent community colour include hispaniclatinx native american black population advance participation representative patient population genentech initiate advance inclusive research site alliance coalition clinical research centre build sustainable ecosystem order facilitate inclusion historically underrepresented people clinical research aim advance participation diverse patient population oncology trial test recruitment retention approach establish good practice leverage industry disease area help achieve health equity people inaugural partner successfully include diverse population clinical trial effort may cancer center san antonio texas oneal comprehensive cancer center birmingham alabama west cancer center memphis tennessee city hope comprehensive cancer center los angeles california recognise bring real change require partnership industrywide investment partner healthcare ecosystem collectively combine scientific advance new technology realworld datum create new standard inclusive clinical research shaping year science pace new drug discover adaptive biotechnology develop rapidly increase develop type personalise cellular therapy exciting time transform deliver care patient commit genentech expand commitment explore uncharted area access previously cell therapy new collaboration sign unreachable target partner adaptimmune therapeutic september envision future latest great develop tcell therapy solid science technology drive innovation tumour collaboration enter unlock future healthcare december lineage cell therapeutic develop commercialise retinal gene therapy pigment epithelium rpe cell therapy specific gene therapy potential address ocular disorder ongoing partnership previously untreated disease replace exist company like biontech mrnabase therapy potential onetime treatment nykode therapeutic dnabase develop quest follow science strengthen therapy aim training immune system presence promise emerge modality recognise patient neoantigen similar year ago roche acquire spark therapeutic vaccine successfully provide lead gene therapy company today spark immunity sarscov infection expertise combine roche broad skill commercial capability global reach advance datum technology patient partner put unique million medical paper position unlock potential gene therapy publish year clinician time immerse late increasingly work area august complex research decide right therapy enter research collaboration license individual patient advance datum agreement shape develop technology analytic enable novel form gene therapy edit genetic clinician well treatment decision message level mrna change fast allow solve problem dna excited work bridge gap healthcare ecosystem develop therapy certain target area drug discovery development approval alzheimer disease parkinson disease diagnosis disease monitor access care rare disease envision future data technology analytic routinely accelerate drug discovery cell therapy development enable well patient care cell therapy promising emerge employee roche group work modality active cell therapy partner bring future study ongoing worldwide close exemplified follow initiative product candidate development cancer immunotherapy cell therapy showing discover select good drug potential effective approach harness candidate person immune system fight cancer follow drug discovery benefit hypothesis genentech collaborate utilise artificial intelligence roche clinical pipeline cancer cell therapie naturepharmaceutical roche envision future late great science technology drive innovation unlock future healthcare pharmaceutical research early development pre organisation develop machine learning operationalisation platform op enable embed machinelearning model daily routine nondata scientist bring fingertip team platform predict different property small molecule enable fast selection good drug candidate follow aspiration roche genentech team company like reverie lab genesis therapeutic generate new compound design predict property advance preclinical development small molecule medicine addition genentech recently acquire prescient design support application optimisation novo design therapeutic antibody power prediction clinical trial computational approach year milestone analyse large amount datum gather clinical trial lead well understanding patient outcome example take risk patient imvigor study urothelial year origin multiple sclerosis autoimmune disease cancer scientist look biomarker central nervous system mystery tcell identify find directly blood assess primary culprit treatment focus patient specific biomarker need additional therapy retrospective analysis stephen hauser current director weill institute datum show patient detectable neuroscience university california ucsf researcher circulate tumour dna ctdna hypothesise bcell component immune system well chance diseasefree play critical role cause inflammation lead well overall survival rate result lead research meet scepticism scientific community directly initiation phase iii study academic funding grant adjuvant bladder cancer prospective selection ctdnapositive patient genentech willing risk agree forward outcome potential change clinical earlyphase clinical trial estimate chance practice improve probability success success decade research able refine new clinical trial allow small short molecule breakthrough open new treatment possibility trial focus patient need additional revolutionise understanding treatment increase data insight capability allow focus vision provide right therapy right patient right time gathering make sense large amount data advance technology highlight fact incredible datum collect stakeholder country system roche group focus well way gather structure sense datum direct datum connection ddc initiative example reinvent flow datum clinical trial site roche automate endto end stream patient trial datum electronic health record ehr system sponsor electronic datum capture edc system ddc initiative eliminate need duplicative manual data entry allow realtime errorfree access clinical trial datum userfriendly software solution test site world receive positive feedback site coordinator study team member able realtime decision patient example work area new partnership alan turing institute uks national institute data science team develop apply advanced analytic methodology generate insight multiple type healthcare datum improve understand impact patient individual disease characteristic response different therapy ultimate goal enhance clinical care people worldpharmaceutical roche product outlicense acquisition agreement divestment product technology discovery licence agreement agreement derive number new exist alliance partnership phc agreement research discovery collaboration japan chugai polivy alecensa mabtherarituxan mabtherarituxan evrysdi tecentriq ronapreve indication actemraroactemra xolair major approval susvimo port delivery system ranibizumab china europe avastin indications gavreto gazyvagazyvaro tecentriq hemlibra venclextavenclyxto azacitidine kadcyla actemraroactemra covid tecentriq enspryng tecentriq pemetrexe evrysdi enspryng ronapreve indication evrysdi xofluza indication xofluza indication oncology inflammationimmunology neuroscience infectious disease ophthalmology pandemic drastically alter scale urgency need develop distribute covid treatment diagnostic testspharmaceutical roche open new possibility fight covid face covid pandemic collaboration jointly develop increase healthcare community look way global distribution regeneron covid address ongoing situation world antibody combination call party acknowledge great responsibility feel embrace new mindset challenge way society couple capability thing expertise ask help result word amazing day know clinical work tirelessly develop testing study successful team complete solution investigate drug substance technology transfer medicine covid understand process usually take month extraordinary mobilisation collaboration take month day roche entire healthcare ecosystem defeat receive manufacturing detail strong partnership deliver product country cornerstone work roche approximately world thank share vision momentum half medicine result successful partnership trial antibody collaboration company institution combination move phase phase iii world know contribute month datum trial early scientific knowledge clinical research promise particularly prophylaxis expertise infectious disease antibody treatment highrisk hospitalise patient base therapeutic skilled workforce enter bilateral agreement specialise manufacturing capability increase number country antibody pandemic drastically alter scale combination authorise emergency use urgency need develop distribute covid receive official approval japan treatment diagnostic test lead july follow november collaborate new way work speed imagine time willingness risk mean reach tireless effort unwavere commitment party include competitor involve possible despite feeling uncertainty fear difficult operating condition global enter partnership lockdown team embrace challenge biotechnology company regeneron embark open mind goal sight develop journey new experience challenge manufacture potentially lifesave medicine jawdroppe milestone impact feel worldpharmaceutical roche elusive diagnosis lifetime perseverance hope age liz adams diagnose spinal muscular atrophy sma rare neuromuscular disorder result loss motor neuron progressive muscle degeneration liz thank positive mindset feel content liz year old start language liz explain point liz walk childhood experienced walking cane enjoy travel physical weakness get old wonder working develop adventurous spirit frequently fall hand shake return home korea run fast friend interpreter deaf work public school time symptom worsen fayetteville north carolina ask parent doctor start long process go doctor liz marry mum kid doctor know wrong sam joyful rebekah david say liz use wheelchair enjoy exercise spending time outdoors usually swim sma know time time week regularly use row year pass finally machine invigorate lot say liz diagnose point parent told excited participate upcoming race people type sma lose ability walk wheelchair overarching attitude point life require mobility perseverance stick liz entire support hard hear dad life love set goal set high determined good goal try reach add year follow diagnosis liz modify version original goal motivate parent figure exercise read lot explain educate sma build support system friend family liz excite recent scientific development sma encouraged growth liz go college study awareness disease decade american sign language pottery start personal experience late handson person challenge turn therapy available away graduate live south korea treatment option possibility amazing month teach english foreign conclude liz smilepersonalise healthcare roche personalise healthcarepersonalise healthcare roche future healthcare lie tailormade solution improve life heart year history commitment innovative science lead lifechange discovery patient recently focus attention early comprehensive diagnosis develop new technology enable advanced diagnostic measurement tool personalise healthcare allow predict likely ill diagnose illness early understand unique effort develop individualised approach characteristic patient condition care date early roche response treatment digital solution help genentech pioneer commonly close gap care continuum area know personalise healthcare phc prevention disease monitor bring target treatment patient effective incorporate thirdparty datum goal today reality combine unique expertise pharmaceutical diagnostic major challenge diagnosis datadriven insight continue preparation speciman dna especially forward remain united goal complex prepare sequence prone integrate element care order create human error launch avenio edge truly personalise experience patient system simplify automate nextgeneration sequence sample preparation reduce human error introduce care continuum advance precision medicine future goal expand personalised healthcare shift treating disease recently introduce open digital focus holistic peoplecentric approach pathology environment enable pathologist span entire care continuum change exchange datum securely provide entail fundamental shift way understand access roche image analysis tool deliver healthcare thirdparty technology sdgs collaboration framework joint ensure care continuum approach development agreement october successful tap deep internal ibex medical analytic global leader resource expertise time artificial intelligence aibase cancer diagnostic capitalise strength independent agreement jointly develop material topic affiliate flatiron health foundation embed image analysis workflow pathologist patient centricity medicine partner external seamlessly access ibexs algorithm insight efficiency stakeholder healthcare ecosystem decision support tool navify digital personalise healthcare help deliver right treatment right patient pathology cloud version upath realworld datum right time enterprise software preparedness age society power data analytic novel sensitive quantitative measure highquality datum rigorous analytic patient empower monitor engine drive phc today healthcare variety disease ability establish produce vast untapped datum deep understanding patient metric hold potential unlock valuable insight daily basis time lead broad range roche diagnostic solution tailor effective care produce billion datum point year single hold highquality datum indicates continuously report information spark small advancement symptom disease effect cancer therapy personalise healthcare bring facilitate share approach disease contribute longitudinal datum management patient care team massive scale enable comprehensive increase survival improve quality view patient life reduce symptom burden emergency room visit hospitalisation maximise true potential datum dataenable technology hinge patient trust continue reliance clinic visit build maintain trust maintain primary way assess monitor patient remain high standard datum privacy deidentification fundamental limitation healthcare personal security additionally increase technology include wearable medical expertise datum handling add device allow patient play active digital health offering portfolio role tracking manage health early roche announce launch multiple sclerosis insidious navify pass important expansion unpredictable disease hard track broad response covid pandemic measure launch smartphone application cloudbase solution consist mobile app floodlight germany finland help individual healthcare professional precision monitor reality people live backend tool testing site navify simple task draw pass enable unconventional pointofcare shape app enable physician patient site fully digitise workflow shed light impact disease test perform government report individual patient furthermore datum point application enable individual store contribute unique datum set design result selfadministere test research forward administer medical facility professional site collaboration moorfield eye hospital london roche pilot home vision monitor remote patient monitoring management interactive smartphone tabletbase app roche forefront diagnostic empower patient test monitor change disease monitor decade vision app design people early develop disease affect macula athome automate selfmonitoring blood agerelate macular degeneration diabetes glucose meter people diabete today moorfield patient usher new era physician use app claiming offer peace ofpersonalise healthcare roche navify pass cloudbase solution consist mobile application individual healthcare professional backend tool testing site mind knowledge document change vision checkup partnership collaboration unlock potential phc integrate advance medical science datum technology care continuum demand holistic thinking collaboration stakeholder healthcare ecosystem commitment accelerate effort partner organisation create new approach solution roche join autism sharing initiative new project build global network share genomics clinical datum accelerate breakthrough discovery precision healthcare autism new technology initiative allow search analysis perform multiple individual datum set information remains protect local environment year milestone june genentech present result collaborative effort pathai improve clinical assessment nonsmall cell lung turning point cancer treatment cancer partnership pathai accelerate century cancer categorise location understand patient response lung body result treatment result vary significantly cancer treatment september fda approve roche genentech breast develop innovative product cancer therapy herceptin regard approval mark digital solution work stakeholder turn point cancer treatment jointly address obstacle phc solution accessible patient world march monoclonal antibody specifically design treat patient roche canada sign memorandum metastatic breast cancer tumour overexpress protein collaboration british columbia cancer herceptin target treatment solid tumour agency canadian personalize healthcare drug pair companion diagnostic innovation network know predict precision identify patient improve riskbenefit profile patient oncology evidence development cancer gain critical time spend search treatment prove successful initiative viable treatment generate assess realworld evidence rwe shape new sustainable reimbursement pathway personalise cancer treatment critical step sustainable healthcare transformation lead well impact pandemic time elapse care low cost people society diagnosis initiation systemic story treatment cancer patient american society clinical oncology asco accept foundation medicine flatiron health study extensive additional work help independent affiliate roche group oncology practice assess address frontline pioneer field healthcare datum impact analytic build clinico genomic database link large leadership rwe regulatory source clinical genomic realworld data policy framework flatiron help establish rwd integrate datum set serve rwe alliance industry organisation valuable resource accelerate precision goal collectively identify develop oncology link patient record advocate technical regulatory policy available research end solution advance use rwe reflect growth year regulatory decision flatiron health furthermore flatiron take major step flatiron health continuously expand ensure interest priority patient network community oncology practice consider research strategy academic medical centre community step include launch formal mechanism oncology partner see daily average patient engagement patient addition oncologist flatiron assist decision foundation medicine support tool quickly select evidencebase roche foundation medicine offer treatment option patient portfolio comprehensive genomic profiling flatiron begin expand network cgp test solid haematological tumour build new partnership derive rwd test enable easy fast well hospital health network europe asia clinical decision partner company lead implementation uptake despite impact covid traditional cgp world goal develop clinical trial prospective clinicogenomic personalise treatment strategy oncology pcg study partnership flatiron smart efficient diagnostic foundation medicine genentech solutions foundation medicine service community academic oncology practice available country worldwide enrol patient metastatic lung cancer site study august japans health authority design seamlessly integrate clinical approve use reimbursement research clinical care offer participant foundationone liquid cdx bloodbase cgp serial genomic testing test analysis cancerrelate access gene solid tumour provide well understanding drive patient flatiron publish important cancer grow give insight personalise study include highlight treatment option patientpersonalise healthcare roche foundation medicine test enable easy fast well clinical decisionmake comprehensive genomic profiling cgp additionally fda approve companion diagnostic claim foundationone cdx foundationone liquid cdx bile duct cancer nonsmall cell lung cancer nsclc foundation medicine companion diagnostic approval fdaapprove test partnership natera foundation medicine launch foundationone tracker research use tracker personalise circulating tumour dna ctdna monitor assay combine foundation medicine tissuebase cgp platform nateras expertise ctdna monitor addition roche launch new genomic profiling kit help cancer researcher sequence tumour send tissue sample centralise laboratory avenio cgp kit power foundationone research useonly allow healthcare professional apply highquality cgp local lab give patient opportunity participate trial leverage cgp foundation medicine update portfolio help expand access precision oncology integration flatiron health oncoemr platform improve efficiency clinical decisionmaking enable electronic ordering order track receipt foundation medicine cgp test result forthcoming integration epic electronic medical record system streamline access genomic insight precision cancer care genomic datum help well understand diagnose treat patient rare cancer personalise level ongoing cupisco study randomise trial cgp assign patient cancer unknown primary cup target immunotherapy treatment aim shed light disease high medical need addition foundationcore large cgp database oncology allow genomic datum help well understand diagnose treat patient rare cancer personalise level researcher learn characteristic ntrk fusionpositive cancer rare molecular subgroup cancer make phc accessible decade pass roche take step field personalise healthcare initial effort lead today deliver innovative personalise solution help million people globe today phc embed organisation maintain clear focus entire care continuum goal make phc accessible technology science constantly shift boundary impossible yesterday grasp today transform patient life tomorrow excite opportunity deliver well outcome people world care tailor individualpersonalise healthcare roche personalise healthcare care continuum enable data analytic early accurate diagnosis ongoing remote care monitoring patient tailor rapid access optimal care plan intervention country foundation flatiron health patient record medicine service available research million growth phc test process navify pass fact partner deal sign companion diagnostic approval community cancer care site fdaapprove flatiron health network foundation medicine test major academic medical centre combine power advanced imaging technology artificial intelligence large database realworld datum provide new insight diseasespersonalise healthcare roche hope future personalise cancer care canada years roche help columbia represent important milestone lie scientific groundwork personalise transform healthcare system canada healthcare treatment target underlie biology person individual disease collaborative project aim reduce target diagnostic help doctor fragmentation improve decisionmake base determine right therapy patient learning patient real time predict unlocking value advance medical science precision oncology evidence development cancer datum technology personalise treatment programme pilot framework approach integrate help guide healthcare decision maker care people demand holistic thinking utilise rwd clinical regulatory collaboration stakeholder reimbursement decision hopeful healthcare ecosystem know meaningful mean early precise diagnosis patient change happen work access right treatment right time ultimate goal scale framework realworld datum rwd patient datum british columbia provinces canada collect routine healthcare practice know learn predict instead clinical trial translate border roche increasingly important fill gap capture affiliate worldwide insight help guide patient diagnose treat demand rwd work regulatory reimbursement healthcare year predict collaboration decision maker continues grow particularly show sign progress patient personalise cancer therapy target british columbia diagnose rare mutation traditional clinical trial precise testing early stage follow evidence limit challenge collect cancer diagnosis additionally key system change integrate datum begin allow tide turn recent decision maker utilise predict framework partnership british columbia canada set work underway expand programme stage hope lead fast new disease area geography predict patient access innovative treatment example partner technology disease area march society cocreate new approach solution roche canada british columbia cancer mindful urgency moment agency canadian personalized healthcare personalise healthcare mean far innovation network sign memorandum improve treatment improve life collaboration publicprivate person hopeful effort collaboration personalise healthcare british area thatpersonalise healthcare roche target cancer unique driver transform patient care kiss young child goodnight evening precious ritual treasured parent worldwide mary bodley cherish moment cancer return treatment success sure give allclear child year ago month later discover lump neck mary diagnose invasive ductal grade bad fear confirm cancer hernegative erpositive breast cancer return receive diagnosis thought mary add complication time young family scared cancer return evolve begin tell family impact hernegative erpositive breast cancer daughter mary say recur herpositive ernegative know go fight finally triple negative thankfully genomic determine communion test able provide treatment option confirmation hear boyfriend work marys tumour girlfriend go different treatment mary live county dublin ireland path keep alive currently sick leave role internal half year say genomic testing huge communication manager roche ireland current treatment work firmly believe reason able cancer tumour stable progress far friend suggestion moment look genomic profiling roche celebrate year anniversary genomic profiling help doctor tailor treatment mary say hope patient unique tumour base individual year roche fantastic people fingerprint process detect tissue create roll medicine cure blood sample mutation cancer dna form breast cancer hope drive growth identify specific bulletproof method prevent breast cancer treatment target individual tumour create implant allow doctor refine tailor treatment woman age base mutation location cancer body incredible work give precious extra time grateful round successful treatment mary kiss girl goodnight give allclear year later eveningaccess healthcare roche access healthcareaccess healthcare roche strive improved access healthcare world roche know lifechange innovation meaningful reach need understand million patient world access quality healthcare multiple barrier continue stand way know country different situation situation exacerbate healthcare system present unique ongoing pandemic contributing challenge draw breadth expertise increase global inequality innovation span patient journey work closely partner develop second year covid pandemic deliver tailor access solution reflect healthcare system world experience countrys individual healthcare need significantly increase pressure time continue work closely important urgent government healthcare provider laboratorie acknowledge share responsibility regulatory authority organisation build resilient sustainable healthcare world increase production system believe comprehensive uhc help critical diagnostic test medicine support stable economy strong society help strengthen healthcare system fundamental addressing inequality support fight pandemic access healthcare particularly lmic minimise impact parallel work accelerate ongoing effort area help improve access quality healthcare goal double number patient receive noncommunicable disease provide innovative therapy low lowermiddle noncovidrelate diagnostic treatment income country end remains delay cancel ambition double patient access novel highmedicalvalue diagnostic solution people access strategy remain focus address world root cause global country level work collaboration global local tailoring solution lmic sdgs stakeholders focus price access world population live lmic programme particularly low middleincome long commit lmic country lmic support effort range programme broaden access achieve universal health coverage uhc medicine diagnostic country access centre business believe harness new technology consider key commitment healthcare improve patient outcome include improve patient outcome bring setting limited resource material topic innovation patient look deeply digital solution navify digital longterm mindset cause prevent access optimal healthcare pathology help virtual diagnosis availability healthcare screen diagnosis treatment train pathologist virtually particularly valuable region limited pathology service key organisation active fight africa develop new tool tuberculosis support patient take active role continue strong partnership disease management example city cancer challenge ccan joint mission create ithemba life mobile health improve access equitable quality cancer application deliver hiv viral load result care city world december education reminder support directly user ccan work city reach smartphone app empower people live estimate million people bring hiv remain adherent treatment engage health professional care extend functionality institution global partner cover cervical cancer address key challenge world loss followup genentech patient foundation provide free medicine approximately program partnership support people year access patient journey partnership echo institute strength pharmaceutical diagnostic work establish remote telementoring position play early role patient programme health worker underserve journey identify barrier access rural community enable diagnose learn great deal partnership treat patient fast effectively apply learning future initiative echo platform connect national centre excellence remote area roche example programme partnership set echo clinic country expand global access program philippine indonesia pakistan india malaysia include sarscov pcr testing increase guatemala canada nations access low middleincome country population launch ongoing pandemic roche officially join partnership award world health establish innovative organization prequalification hiv publicprivate partnership hcv test guideline include president emergency plan aid relief cobas mtb cobas mtbrifinh tests pepfar george bush institute unaid cobas system patient live merck committed create area limit healthcare resource healthy future woman aim reduce prequalification ensure access high new cervical cancer case quality diagnostic woman live hiv african country diagnostic division continue partnership nonprofit organisation red share responsible approach medicine pricing mission emphasise importance diagnostic endeavour ensure affordability testing fight covid barrier access pricing ongoing hivaids epidemic mitigate medicine innovation seriously impact covid health system pricing strategy reflect definition fair order reach patient access limited pricing balancing need affordability roche join world economic forum end incentive innovation need workplace initiative coalition company patient today tomorrowaccess healthcare roche long commit low middleincome country order broaden access medicine diagnostic like healthcare stakeholder believe differential pricing effective solution address affordability constraints specific country international differential pricing idp approach allow local organisation adjust price reflect countrys relative income ability pay ensure innovation fairly price reach patient need approach proven greatly improve patient access innovative medicine particularly develop country price primary barrier partnering improve access women health work women health exemplifie tailor approach access roche commit womans health stage life support need reproduction fertility pregnancy disease prevention treatment variety diagnostic screening monitoring assay innovative medicine effort support improve women health align year milestone global strategy womens children adolescent health woman child movement revolutionise care people live hiv enter diagnostic space roche strong key example commitment work focus infectious disease follow identification hiv women cancer breast gynaecologic forefront develop diagnostic cancer effort combat cervical cancer hiv particularly molecular test early infant diagnosis viral work country strengthen load testing monitor treatment response revolutionise healthcare system help establish national management care hivpositive patient cervical cancer programme eliminate disease annual cervical cancer enable equitable access hiv testing resourcelimite setting death occur lmic help support unaid target roche create global access overcome barrier care specifically program programme roche provide sustainable increase awareness screen roche pricing government funder work partner build collaborate partner help country infrastructure capability require run diagnostic programme implement national hpv screening treatment year million people africa use viral load testing programme story manage hiv infection date million baby test hiv roche test asiapacific region hpv continue responsible majority cervical cancer case country cervical cancer support programme world aim increase access diagnostic treatment breast cancer copy spread second common cancer august apec roadmap promote sustainable economic advancement woman cervical cancer prevention control officially endorse member asiapacific economic cooperation apec roche contribute development new roadmap include cervical cancer screening especially hpv molecular testing breast cancer overtook lung cancer world commonly diagnose cancer responsible cancer death woman line new global breast cancer initiative focus womens health increase number people treat perjeta china august august see breast cancer patient switch phesgo subcutaneous fixeddose combination perjeta herceptin short invasive mode administration reduce number patient receive medicine intravenous infusion freeing capacity hospital well access future look forward work expand access continue priority working partnership stakeholder healthcare spectrum government payer nongovernmental organisation multilateral insurance company continue develop tailor solution help overcome barrier create rapid broad sustainable accessaccess healthcare roche woman cancer hepatitis diagnosis kenya pakistan roche support empower programme partnership support seek contribute prevention early diagnosis underprivileged people treatment education woman community hepatitis testing diagnosis breast cervical cancer access project bridge world latam initiative implement pink consulting room national programme aim colombia cervical cancer elimination address problem breast cancer diagnosis treatment roche support set cervical cancer screening triage pink consulting room test thailand million woman diagnose support thailand goal eradicate cervical cancer roche partner government healthcare community raise awareness hpv dna testing include chile peru mexico working collaboration healthcare system partner key resolve critical access barrier therapiesaccess healthcare roche tackle healthcare great challenge women health roche challenge curb spread life entire healthcare system bring lifechanging threaten disease roche cobas solution patient globe instrument covid testing society expect cervical cancer screening come work day relentlessly game changer look need tomorrow hope allow country day vision bright healthy world infrastructure place prior pandemic reality pass year bring utilise machine help address significant new challenge include access diagnostic gap women health treatment disease like cervical cancer lifechange innovation impactful cervical cancer case result reach need global human papillomavirus hpv sexually cervical cancer death occur middle low transmit infection vaccine income country diagnostic discrepancy exist despite preventable disparity prevalent vaccination screen approximately adjust focus develop woman succumb disease deliver advanced diagnostic solution year make common cause address significant disparity cervical cancer death woman cancer especially region burden disease peak roche add hpv country move hpv dna testing screen global access program effective efficient disease cuttingedge diagnostic solution available prevention strategy fact world health woman great need organization recently endorse firstchoice method cervical cancer screen world watch waiting advance recommend clinical guideline women health july evolve favour hpv test firstline primary announce update screen guideline screening support interest improve help realise goal eliminate cervical outcome availability technology cancer diagnostic division remain help laboratory achieve efficiency scale commit investing advancement need meet demand highvolume significantly improve prevention strategy cervical screening programme provide woman protection care deserve empower woman control rapidity scale comprehensive health lie core ambition testing portfolio develop transform healthcare progress pandemic leave wonder know hpvassociate cancer statistic centre disease control prevention fact sheet cervix uteri world health organization recommend dna test firstchoice screening method cervical cancer prevention world health organizationaccess healthcare roche word save live agn kraidy journalist activist abidjan cte divoire breast cancer survivor campaign woman access diagnostic medicine information feel lump leave breast small public health system clearly noticeable agn explain know current work government herceptin right immediately go free herpositive breast cancer patient company doctor check aithough nonsurgical treatment available happy basic diagnostic doctor recommend mastectomy need biopsy realise like woman cte divoire sophisticated ensure treat little information knowledge correctly agn ask simply breast cancer despite fact healthcare professional wellequippe disease affect approximately woman hospital number patient need country year half diagnose survive geography prevent access cte divoire oncology centre locate give hope change perspective abidjan mean long journey high ultimately agn ahead accommodation cost live outside mastectomy determine city centre obstacle woman cte divoire need learn people simply afford cost dreadful illness want able month treatment say agn share knowledge affect roche support setting write book journey new oncology centre bouak bring lesson learn way unsurprisingly screen diagnosis followup close fous les boules vaincre cancer living part country catalyst large awareness campaign country word save live partnership people power obstacle step patient journey create solution barrier patient face despite awareness raise thank wish challenge status quo agnss effort people cte divoire face cancer ignorance agn multitude barrier access diagnostic advocate ongoing investment awareness treatment deserve campaign patient support programme barrier affordability treatment partnership different sector reimbursement policy cancer treatment close collaboration despite numerous challenge agn look government roche help increase positively future thankful access highquality care country improvement focus instance agreement continue save life national programme cancer provide continue overcome barrier bring effective free testing herpositive breast cancer solution patient cte divoirepeople culture roche people culturepeople culture roche rocheproud pandemic change personal professional routine reaffirm connection share purpose strengthen sense belong pride work roche happiness engagement people know important role play critical fundamental success global supplier healthcare solution conduct biennial global employee opinion evident covid survey geo seventyeight percent pandemic business continuity roche employee participate survey circumstance carry high expectation share happy work roche result especially satisfy take special care consider survey follow implement adequate onsite safety measure particularly intense period undergo critical protect employee research purposedriven transformation maintain development manufacture global supply relentless focus ongoing business initiative chain work diligently ensure time work ensure safety global support function remain supportive people patient particularly work customer premise face covid pandemic likely expose virus health safety employee ongoing pandemicrelate paramount key maintain reliable challenge face unpredictable supply medicine diagnostic solution difficult situation people patient customer need remain highly engage evidence score commit go extra mile ensure unchanged geo aspect work include workplace survey result roche quartile thirdparty manufacturer supplier global healthcare industry accord remain safe healthy geo benchmark validate continue effort sustain great work environment unprecedented time mental physical wellbee employee demand clear survey people great focus help support aspect happy work roche enjoy inclusive number assistance programme reward culture feel optimistic place programme provide guidance sdgs future positive impact patient work home mental health nutrition ergonomic social wellbeing sleep fitness focus safety wellbee mindfulness resilience people company commit serve global live week september material topic need patient society employer renowned keynote speaker share insight talent attraction commit provide safe inclusive resilience friendship happiness retention work environment enable people offer multiple complementary activity organisational agility grow thrive reach potential onsite virtually range online yoga patient centricity culture peoplecentre purposedriven fitness class day resilience challenge diversity inclusion work culture ensure employee thrive critical aspect culture providing deliver good work inclusive work environment authenticity remain true respect inherent sense belong employee feel comfortable presenting nurture ensure maintain environment choose confident explicitly emphasise diversity inclusion protect discrimination base crucial roche history gender culture race sexual orientation cultural identity aspect free focus good work ensure measure introduce update vision accurately integrate inclusion strategic pillar establish index geo council oversee strategic overall society advance positive change society governance ensure properly pillar foster supplier vendor integrate business strategy diversity invest stem science technology engineering mathematic activity inspire update strategy focus pillar support future talent patient address unmet need diverse patient community additionally senior leader demonstrate specific activity pillar include diversity strong engagement individual clinical trial inclusive research example commitment share empacta evaluate minority patient organisation actemra global phase iii covid clinical trial design specifically enrol patient course year celebrate population underrepresented multiple event activity include clinical study disproportionately choose challenge campaign affect pandemic launch connection international people build workforce reflect women day iwd continue society serve year campaign call participant pillar increase data transparency gender bias inequality celebrate release gender pay equity report base women achievement include photo organisationwide analysis take challenge encourage roche employee consideration global grading job structure level raise hand solidarity iwd organisation etc find significant challenge status quo great gender difference pay man woman equality world similar job accordance united nations sustainable development goal number pride month june highlight achieve gender equality empower celebrate affiliate world woman girl continue commit roche switzerland award advance opportunity lgbtiq certification swiss lgbtilabel woman organisation notably organisation certifie swiss company increase proportion female leader advocate internal equality lgbtiq executive position additional communitypeople culture roche proud inclusive work environment authenticity respect inherent sense belong nurture month november bring employee organisation intensify commitment diversity inclusion employee choose virtual event inspire discussion engage session unconscious bias training advance inclusive research health equity neurodiversity recognise value uniqueness individual regardless gender race age skin colour religion marital status sexual orientation heritage physical mental ability roche tolerate discrimination shape form furthermore firmly condemn type harassment mental physical sexual infringement violate employee right dignity respect workplace stance strengthen update employment policy deeply convinced success depend talent performance dedicate diverse workforce strongly believe potential single employee remain committed unlock potential people bring purpose life live new way work create truly diverse inclusive workplace live new way work directly impact ability achieve longterm ambition deliver purpose patient need believe great idea arise collaboration cocreation ask tough question exchange perspective challenge shift paradigm capable innovate develop lifechanging solution increase use technology digitalisation introduce number new approach tool provide people aroundtheclock support rapidly change environment prompt think differently sustain competitiveness strange change capacity adapt undergo transformation dna found year ago reinvent advanced science technology adjust way work multiple time history recent implementation agile working methodology operating model boost speed efficiency deliver solution patient healthcare provider pandemic force physical distance revolutionise way work make agile collaborative roche continue broad transformation journey despite confusion uncertainty create pandemic people show engagement dedication cocreate future shape year milestone healthcare system challenge time alice keller shatter glass ceiling alice keller talent talent emil barell ceo roche evolve way lead recognise bring company new way work hand hand feel brilliant people care convention new way lead roche employee time man woman matter champion deserve work thrive great leadership excellence form operate seven leadership commitment year post alice position japan day journey time role leader boat arrive tokyo handle countrys product launch evolve continue correspondence basel alice love japan unsurprisingly excel role year promote director past year continue roche japan make woman senior executive roche utilise kinesis synergy senior leadership sensational development time development programme pandemic force rethink way organise run woman like alice pave way inclusion people diverse programme event instance global background experience skill perspective key virtual leadership development initiative success today future launch virtually incidentally give broad audience access valuable toolpeople culture roche implementation agile working methodology operating principle boost speed efficiency deliver solution patient healthcare provider agile need shift share leadership foster trust ownership evident develop networked organisation decision long silo high interconnectedness interdependence company approach require leader apply vacc principle visionary architect coach catalyst lead serve team organisation vacc leadership approach align creative mindset support cocreate vision allow achieve result actively authentically drive change enable role model continuously push learn empowerment unique effort investment develop coaching skill leader recognise international coaching federation icf autumn award icf prism award special mention award recognise roche approach make coach integral element leadership culture fulfil high professional standard create measurable positive impact introduce number new approach tool provide people roundtheclock roche want build capability support additionally set broad range lead learn encourage selfleadership internal external training learning foster learn mindset help opportunity design strengthen people thrive achieve refine foundation agile selforganised workplace exist people development strategy provide portfolio activity train support business function people culture selfgrowth individual leadership undergo significant transformation refresh workforce strategy revamp enhance everyone experience organisational growth effort update unveiled new approach engage core process practice thank develop employee year ago effort people culture set goal agile organisation efficient strategic partner take significant step increase establish new standard use technology digitalisation improve creation value longterm success employee experience organisation pandemic provide tailor resource support employee work home include ergonomic assessment occupational health safety pandemic continue impact operation roche manufacture relate activity keep run time country decrease case number operation resume onsite temporarily country employee continue work remotely site manage pandemic locally uniform riskbase approach mitigate likelihood workplace transmission offer sarscov test case vaccination employee work onsite home site provide tailor support resource employee work home consist information programme maintain health wellbeing support set ergonomic work environment home remote access employee assistance counsel roche actively support possible community employee health safety programme deliver vaccine provide upto date evidencebase information dismantle barrier employee vaccinate sarscov influenza primary objective provide safe workplace employee offsite occupational accident include operate motor vehicle present significant risk roche actively manage risk management programme include current set goal aim continuously improve safety employee goal roche accident rate rar rar correspond number work day lose occupational accident employee year reduce vehicle collision million kilometre losttime illness rate roche accident rate working day lose year accident number workrelate accident roche accident rate threeyear averagepeople culture roche employee region africa north america asia parttime australianew zealand fulltime latin america europe total workforce pharmaceutical management diagnostic bod chugai cec corporate woman employee odg number employee express fulltime equivalent base headcount exclude chugai arm length alliance agreement roche majority shareholder chugai retain autonomy operate divisional grouppeople culture roche lifelong career roche han aeberhard embark roche apprenticeship basel imagine eventually retire company year month day han grow basel common switzerland people strove discover develop teenager complete short apprenticeship potential hanss colleague close final year school decide heart meet lot people share career concrete vocation experience expertise helped grow mind han know profession explain fact colleague technical offer good prospect friend growth development choice chemical technician influence challenge teacher enthusiastic career handful opportunity exist roche old challenge hard reorganisation brother start apprenticeship involve downsize difficult chemical technician year early sustain highperforming team approve happy path choose department get reorganise say especially han say job bore able goodbye great people develop professionally personally work innovative environment past year pandemic challenge manufacturing sector highlight han wife work look plenty highlight fill home period provide way han pride fond memory deep ease retirement august appreciation roche familyowne generation leadership convince new chapter life reflect culture employee year advice han offer treat respect colleague successful fulfilling career perseverance manager alike thing tough authentic speak know hold work cutting edge innovation explain lastly team player respect technology key motivator colleague pioneer liquid crystal technology mid set stateoftheart fully look year han hope computerised manufacturing building campus roche sustain unique legacy early year digitalisation employee patient core hope family stay personal highlight include promotion happy healthy retire han foreman line manager lead fully disconnect profession people job personal son decide follow footstep commitment develop genuine interest pharma technologistsenvironment roche environmentenvironment roche environmental protection go achievement know today safety security health environmental protection roche conceive industrial accident roughly year ago blast subsidiary italy reputation audits consulting training know today seveso incident result culture combine professional release toxic chemical air risk management system minimise risk aftermath incident bring expert team roche site identify risk standardisation industrial safety regulation develop mitigation plan communicate greatly influence future policy guideline employee roche stakeholder support implement necessary measure seveso incident tragic huge opportunity roche evolve environmental challenge approach environmental protection occupy year include late protect environment waste emission air water integral operation approach today climate change forefront sense responsibility change climate introduce new risk methodically issue concern resource scarcity heighten occurrence quality productivity cost efficiency natural disaster roche operational possible economically viable strive risk management strategy include forecast continuous improvement seek evaluate financial implication sustainable longterm improvement change situation extreme weather water behaviour adapt equipment scarcity operation recent standard develop innovative process organisation order develop environmental ensure disaster like seveso incident protection goal current fiveyear recur devote special attention prevention goal period run goal sdgs reduce risk key effective set area people environment environmental management business challenge achievable manage professionally proactively company production operation maintain current high level world roche expose risk performance standard possibly damage people good environment organisation material topic energy efficiency longterm mindset embrace environmental responsibility environmental responsibility guide roche offer supply chain partner renewable activity year start report energy combine competitive rate greenhouse gas ghg emission early project research gauge implement receptiveness supplier offer carbon dioxide reduction measure lead actively support sustainability journey combine decrease carbon dioxide provide commercially valuable solution generate operation scope monitoring result determine purchase energy scope strategy extend offer highspend highemission supplier represent operation impact roche spend extend far past company gate purchase small diverse supplier material component service enable develop manufacture product area focus partnership patient need form concern reuse material number environmental responsibility collaboration project establish complete total ghg emission inventory supplier understand opportunity include emission associate reduce level waste include plastic interactive good service purchase roche workshop hold key supplier focus extend focus hot spot singleuse technology filter look supply chain develop mitigation strategy way recycle reuse substitute material benefit environment minimise carbon footprint parallel bring future sustainable longterm financial reputational benefit electricity come roche supplier sustainable source continual pursuit reduce ghg emission scope support supplier scope source develop clear effective managing extend ghg define process generate progress set responsibility identify good way challenge realistic goal develop action work different segment supply plan achieve goal base identify supplier implement pharmaceutical diagnostic division product service account nearly scope programme constantly evolve onethird total carbon footprint engage new innovation available supplier active dialogue work month finalise scope carbon develop sustainability reduction strategy set target base strategy partnership encourage potential reduction extend number great transparency well decisionmake supplier actively collaborate outline expectation longerterm ambition support supplier effort gradually productspecific decarbonise operation process reporting supplier strategy involve pilot project monitor carbon dioxide reduction inform partner ukbased energy supplier product choicesenvironment roche commit sustainable energy future implement innovative technology improve energy efficiency power people drive change roche voice hear contribute sustainability effort share idea innovation platform touch aspect sustainable development agenda environmental social include human right economic refresh supply chain sustainability council internal decision make body executive level review idea business case decide one resource implementation support level focus prioritisation sustainability business allow idea concept turn impactful deliverable widescale change scope strategy execution centre key theme reduce reuse recycling involve influence business travel steering sustainable energy future behaviour reduce spend nonessential good service recycle reuse material roche recognise climate change large global risk substitute innovate address matter urgency expert team problemto involve substitute nonsustainable solutionfocuse mindset address global issue energy sustainable energy consider year greenhouse gas ghg emission roche originate environmental stewardship product design transformation use energy instead compensate alternative logistic method route offset team pursue programme actively reduce ghg emission engage partner supplier priority include reduce energy consumption increase supply chain energy efficiency substitute energy sustainable involve transition supplier source measure reduce ghg emission renewable electricity incorporate basel kaiseraugst site example sustainability core element global supplier energy consumption building operation minimise relationship management strategy innovative design heated waste heat heat environment carbon dioxideneutral way continue optimise recognise deliver sustainable energy use company strive goal supply chain build reduce scope ghg emission zero exist industry collaboration extend reach influence learn industry approach sustainability environmental performance datum continuously monitor environmental impact approximately put performance aim collect datum clear path reach key performance indicator ensure compliance high commit contribute sustainable standard objective guarantee energy future vision reality process equipment state art implement innovative technology improve show progressive improvement energy efficiency increase use reduce environmental footprint roche sustainable energy consideration positively measure environmental impact eco impact environmental footprint example balance metric measure environmental dramatically reduce ghg emission impact pollutant emission resource extraction activity ecopoint unit quantity greenhouse gas reduction effort point add relate total number success reduce energy consumption employee enable monitor carbon dioxide emission credit environmental impact employee take business roche ghg management approach growth account reduce example diagnostic site meylan france roche site reduce ghg emission stationary source heating purchase electricity zero site consist new energyefficient building provide electricity sustainable source biomethane site focus car year milestone fleet strategy optimise emission nutley site embody roche legacy roche technical production site roche take environmental responsibility seriously determine heating ventilation air conditioning system create longterm social value communities nutley remediation cleanroom optimise area project exception nutley site close roche utilise high ventilation rate meet room air quality commit make sure acre headquarters requirement optimisation reduce carbon carry legacy innovation social responsibility dioxide emission approximately tonne year result annual monetary saving pioneer approach environmental investigation remediation approximately chf project novel divestment strategy cut year traditional timeline expand pharmaceutical production attract developer property sell roche site estimate monetary saving retain responsibility site cleanup increase approximately chf million year maximum reduction carbon dioxide call campus boast research institution private emission tonne year clinical laboratory approximately employee compare site close tenant include healthcare biotech similar ghg reduction measure place retail hospitality leader vision contribute fiveyear goal sustainable area economic social wellbeing generation come energy future activity result reduction carbon dioxide emission scope sourcesenvironment roche water consumption noise pollution energy consumption landfille waste emission water emission air roche ecobalance stipulate company car fleet consist vehicle use mjkm vehicle operate energy sustainable source grid electricity company vehicle priority reduce usage energy energy use energy use look way improve efficiency heat recovery select type addition encourage use renewable business air travel energy make sense natural gas video teleconferencing facility establish site widely employee encourage use train consolidate business trip scope scope capital good scope scope scope ghg emission ghg emission ghg emissions purchase good scope scope service scope fuel energyrelate activity transportation distribution waste generate operation business travel use sell product sustainability priority site kaiseraugst switzerland example energy consumption building operation minimise innovative design direct emission operation indirect emission purchase energy emission result activity supply chain verify methodology base ghg protocol environmentally extended inputoutput model methodological inaccuracy evolve complement refined datum available number serve baselineenvironment roche energy consumption terajoule total scope scope energy scope scope consumption gjemployee gigajoule halogenate hydrocarbon tonne inventory release global inventory include chugai genentech ventana include datum additional roche site wide scope halogenate hydrocarbon previous year emission air tonne voc particulate nitrogen oxides sulphur dioxide volatile organic compound water usage discharge water withdraw million water consume million organic matter discharge waterway treatment heavy metal discharge waterway treatment landfille incinerate waste tonne nonhazardous hazardous contaminate soil hazardous construction waste nonhazardous contaminate soil remove reduce remediation activity kesslergrube germany increase hazardous waste reallocation electronic waste hazardous waste environmental datum spark therapeutic flatiron health foundation medicine include roche environmental resultsenvironment roche manage risk people environment asset peter schnurrenberger team evolve safety security health environmental protection function integral business activity past year drive strong belief protect people quantity quality water matter environment asset integral society accept nonnatural success company betterment chemical water know need society peter team develop reduce pollution chemical comprehensive management system particular readily decomposable embed organisation possible need transparent core pillar business associate risk versus benefit societal expectation increase time standardise information area focus reflect law regulation roche transparent people realise report advocate harmonise act protect planet reporting system know society benefit future generation say peter know increase knowledge reassurance despite progress today standard drift apart opportunity improve far complex detailed create lot bureaucratic burden questionable value look future peter see relative effort say peter need work number key issue tackle stakeholder create simple informative organisation obvious area climate change robust reporting framework say want reduce associated risk need bold action roche set goal finally increase global dependency eliminate greenhouse gas emission risk event widespread impact increase develop roadmap goal global healthcare company need action plan implement prepare situation area business fast act ensure uninterrupted supply product greenhouse gas atmosphere patient peter say responsibility patient society drive force key issue water basis activity take lightly end life indispensable basic material day know order achieve goal manufacture pharmaceutical diagnostic need educate highly commit passionate product water scarcity increase people drive effort lot region world need work responsibility clean water reduce water activity forward order protect consumption reuse recycle health safety wellbeing generation feasible peter reflect comecommunity engagement roche community engagementcommunity engagement roche community impact lasting tradition philanthropy roche year remain committed make sustainable difference community operate commitment society long philanthropic partnership local nongovernmental organisation ngos international committee red cross support early childhood development icrc begin support icrc education effort world effort help displace hungry europe year partnership response pandemic relate restriction icrc continued evolve grow gathering employee get creative sdgs reinvent event include wide range found member innovative fundraising activity icrc corporate support group event include plogging combination jogging support icrcs access water initiative pick litter south korea volunteering mali total million people benefit orphanage cte divoire walking meeting programme proud challenge spain virtual boxing workshop endure partnership organisation like colombia total people icrc collaborative effort site country participate difference community world fundraising activity partnership core pillar year colleague nominate employee longterm approach philanthropy ambassador visit react children project wellestablishe strategy maintain clear witness firsthand impact focus engagement philanthropic fundraising activity group strategy build pillar community ambassador virtual visit child dream project support art investing react new partner ngo focus education provide humanitarian support children education southeast asia strictly adhere specific criterion partner project selection process visit ambassador chance criterion include quality innovation meet founder child dream sustainability school computer lab help build cambodia hear directly student grassroots community engagement scholarship change big employee engagement lives meet person ideal virtual philanthropic event roche children walk immersion truly inspirational money event begin employeedriven save travel go local children ngo material topic pilot project site basel nutley ambassadors respective country learn longterm mindset palo alto fund raise walk child dream story availability healthcare react independent global charity art mean connect community young commission engage new contemporary long history support groundbreake classical composer expose scientist contemporary art cultural project include leadingedge experience sound exploration parallel innovation art innovation science exposure new young composer australian idea perspective help foster culture bear kirsten milenko debut new piece traho openness creativity roche help pay homage unfathomable loss australia promote diversity inclusion celebrate experienced result wildfire rage different culture discipline result loss billion animal million hectare begin collaborate lucerne burn land piece musician sing festival international festival contemporary tribute perished help classical music unique project call roche memory alive public mind commission year commission new orchestral work world nationality represent roche talented composer start commit diversity inclusion partnership extend include roche support project like culturescape multidisciplinary swiss festival promote crossborder cultural dialogue help celebrate diversity bring unique facet employee year milestone culturescape focus amazon region bring artist brazil colombia peru good clean health south africa ecuador switzerland topic explore phelophepa mean good clean health sotho million festival include climate change access people rural south africa mean access affordable primary water violence peace collaboration healthcare roche transnet freight logistic company festival wideranging roche phds come establish phelophepa world comprehensive postdocs employees latin america primary healthcare facility rail access performance workshop artist start threecar train expand coach train provide range healthcare service include dental bring benefit event ophthalmological psychological general health main external people possible roche brazil host virtual sponsor roche provide additional support covid pandemic culturescape week week include protective sanitise equipment share music artist provide transnet launch train support phelophepas covid response people vaccinate patient receive basic healthcarecommunity engagement roche roche young commission recipient kirsten milenko follow debut new orchestral work traho sale shaman indigenous huni kuin people brazil perform burn instrument orchestra culturescape amazonia mind body workshop offer talk social issue artist explore work extend workingfromhome period event provide valuable outlet connect colleague creativity explore diversity inclusion new way feel sense pride engage roche philanthropy get student excite stem roche science technology heart commit support interest discipline young people international local programme improve access education realworld science technology hope support generation innovator year roche support swiss youth science promote science technology young people found sponsor international swiss talent forum organisation think tank programme annual meeting bring young people world discuss current global issue proud support host science switzerlandwide school competition run biennially cooperation simplyscience foundation school participate present project theme smart system jury roche scientist academics industry expert win class sciencethemed trip london healthcare worker volunteer day fund ngo commit reduce childhood stunt indonesia show mother impact poor nutrition children health roche helped establish countrys impact stunt centre excellence go healthcare company commit build strong healthy community support human social service system place need seek partner aim implement simple meaningful measure result last improvement sustainable impact society example support day fund indonesia establish help reduce childhood stunting condition define shortness height child age arise prolong malnutrition affect physical cognitive development support ngo establish countrys impact stunt centre excellence provide tool training community healthcare worker parent additional centre open directly benefit people include healthcare worker parent child addition model garner support ministry health attract new donor enable continue scale integrate healthcare system ensure sustainability project include ability central philanthropy roche sustainable way support community global philanthropic secondment programme allow roche employee volunteer ngo support global health education walter lee roche diagnostic photo support terre des homme children aid organisation define model introduce new global health technology digital stethoscope low middleincome country improve outcome childrencommunity engagement roche international committee red cross support icrc year found member icrc corporate support group contribute water habitat activity country africa million people benefit access water initiative mali child dream world wide fund nature working child dream recent react partner improve education wwf cofounde lukas luc child southeast asia hoffmann grandson roche founder fritz hoffmannla roche wife adle roche student benefit new continued support wwf classroom computer labs scholarship partnership cambodia people benefit rebuild effort nepal kenya zimbabwe achieve unicef swiss youth science work support access education child disadvantage background country africa support swiss youth science asia seek promote science technology young people year child benefit educational programme ethiopia malawi student reach nepal philippine swiss youth science programme phelophepa healthcare train main external sponsor phelophepa free mobile healthcare clinic travel rural area south africa journey year ago million people benefit basic healthcare service training job phelophepa south africacommunity engagement roche balance heart head help child dream reality marc jenni daniel siegfrie give career banking set charity children asia start build association deliver health education important hope good philanthropy require perfect balance marc sit little guest house heart head heart need blank piece paper night understand care people idea form happy try help head stay develop meaningful rational good decision productive partnership daniel talk secret success organisation establish partnership child dream charitable notforprofit roche clear area focus organisation support child young cambodia improve school building infrastructure adult myanmar laos cambodia thailand fiveyear goal new primary secondary cofounde marc daniel high school classroom benefit student organisation employ people year support computer laboratory facility work reduce childhood mortality improve aim fully equip computer health hygiene school community laboratory vastly improve skill increase access quality education knowledge finally back high school scholarship help marginalise student improve marc daniel admit balance job social mobility opportunity easy maintain current situation myanmar particular absolutely devastating partnership work share say daniel make difficult purpose roche engage work emotional lose balance say daniel impact real year manage provide new school building thousand navigate line deliver meaningful change child cambodia real hope thousand child marginalise difficult background computer lab come digital literacy meaningful mission important bring new opportunity set child dream successful unfulfilling career bank switzerland hong emphasise difference kong singapore experience provide mean travel gateway southeast asia realisation world mean social worker challenge face local child network family member realisation pivotal neighbour local community try moment daniel basically epiphany maintain balance heart head want meaningful say marc remember big suggest set children charity say storm sun come shine againbusiness ethic roche business ethicsbusiness ethic roche integrity driver business ethic uphold high standard ethic integrity sustainability comply law regulation make positive impact society roche believe integrity basis strengthen share ethical mindset sustainable successful business start organisation employee responsibility behave integrity accordance foster collaboration oneroche share company value compliance guideline approach commitment reflect distinct business expectation place partner partner roche group know world require distributor supplier foster collaboration oneroche service provider meet integrity approach key overall success standard emphasise sustainability expect approach drive force business partner help foster social compliance risk opportunity management economic development community effort operate example initiative aim continue focus effort enhance effectiveness collaboration stakeholder understand trust assurance function include limited organisation help ensure trust compliance quality safety health environment remain independent political affiliation insight comprehensive collaborative spend chf million switzerland gap analysis reveal high level competence spending include payment industry key area move forward great association chamber commerce opportunity continue foster collaboration financial assistance trade union donation assurance function ensure roche political party cantonal federal level hold high standard provide donation political party low pragmatic solution business sdgs doubledigit thousand range swiss franc ultimate goal improve patient live account approximately total contribution donation build common set value division country example demonstrate covid pandemic impact want holistic consistent material topic work roche include sustainable approach compliance human right ensure compliance affiliate worldwide ethic transparency implement new way work harmonised compliance risk patient centricity empower compliance network focus opportunity management process availability healthcare collaboration exchange allow division intent initiative improve compliance efficiency minimise redundancy enhance form team supplier risk transparency management professional provide support enable procurement team overall review approach rest organisation business ethic incident management develop stateoftheart tool facilitate risk develop new system internal non assessment management compliance case management reporting system enable strong collaboration provide support employee work different function involve management procurement source implement new case especially compliance internal online diligence tool tool provide investigation team people culture guidance mitigate risk relate finance supply sustainability technology intellectual collaboration patient property quality contract guidance evolving improve internal base inherent risk associate process strive engaging type supplier expect important dialogue outside roche engage know learn great deal patient adhere stringent ethical standard key work mitigate risk protect impactful effective interaction human right develop supportive coaching tool roche commitment human right reflected call compliance patient engagement navigator stringent requirement place tool support business identify supplier worldwide applicable principle rule provide regard supplier service provider robust guidance enable roche employee partner effort create build compliant sustainable relationship relationship mutual trust collaboration patient patient organisation order ensure standard meet story important element relationship adapt meet change need supplier sustainability assurance visit programme healthcare system continue transform ssav give ability positively rapidly look respond effectively impact labour condition supplier facility spend money late roche roche supplier code conduct bind finalise new policy thirdparty spend supplier adhere clearly state performance policy move provide tactical guidance expectation include performance human focused procurement activity provide right allow roche conduct ssavs help rochewide principle parameter govern ensure compliance collaboration spend money new framework allow capability building supplier evaluate set operational procurement rule annually standardise riskbase process process local level establish identify high risk human right globally applicable diligence sustainability violation vulnerable population child requirement underage worker migrant local underprivilegedbusiness ethic roche modern safe remediation method kesslergrube site grenzach germany protect water nearby rhine river community people low level education supplier determine high risk include ssav programme look future essential constantly develop expand human right requirement guideline order ensure continue meet high possible standard update methodology address industry sector previously consider nonorganisation economic cooperation development oecd country performance standard lower human right risk associate certain commodity ensure properly address issue child labour integrate unicef children right workplace index methodology identify high risk supplier inclusion ssav programme despite ongoing challenge covid year milestone pandemic roche continue ssav programme carefully develop remote auditing protocol adopt hybrid virtual onsite generation come approach conduct ssavs kesslergrube site germany serve emea apac north america mixed landfill domestic industrial chemical waste latam human right relate local community business include roche eventually area observation graph cover authority decide need remediation order protect local groundwater resource follow audit supplier commit adjacent river rhine document corrective action plan address audit find ssav programme include recognise social ethical responsibility protect followup audits verify corrective action environment generation come begin adequately address identify finding complex remediation project germany ongoing today go way legally require goal eliminate human right come exist soil groundwater contamination possible example illustrate partner proactive approach create positive impact make supplier help increase human right standard remediate area available reuse effort reduce environmental impact convert roche fleet electric vehicle work closely supplier world ensure adhere high ethical standard area business protect human right key effort believe greenhouse gas reduction come expense human right objective ensure manufacturer provide electric fleet vehicle compliance oecd guidance responsible supply chain able trace conflict mineral smelter refiner compliant human right expectation accordingly supplier electric vehicle compliance oecd guidance ethical mineral source code conduct protect miner family recycle programme conflict mineral roche cease negotiation electric vehicle manufacturer refuse supplier code conduct right audit equivalent sustainable supplier code conduct policy compliance business supplier refuses accept principle supplier code conduct employee roche group speakup line operate right audit compliance external provider available language countrie sustainability principle chief compliance officer receive report allege violation code conduct business ethic incident reporting system unfounded found invqesutoigtaetio result employment contract agreement business partner terminate ground unethical behaviourbusiness ethic roche general packaging administrative service excessive overtime lack labour policy practice contract research facility maintenance human rightsrelate organisation finding excessive overtime incorrect industry lack labour policy excessive overtime compensation overtime delay payment wage laboratory supply logistics transportation inadequate maintenance employee time record incorrect overtime compensation grant annual leave incorrect deduction wage patient heart work closely patient community listen learn integrate feedback aspect workbusiness ethic roche reflect responsibility patient look history humble concession day trust patient family place today live insight guide trust research medicine help improve patient experience diagnostic develop integrate diagnosis treatment ongoing monitoring solution launch help improve patient support work engage patient quality life responsibility patient right way centralised global care drive force patient partnership team worldwide patient approach patient partnership partnership network partner company drive collaboration patient year work community core geography understand gap exist treatment disease like cancer multiple sclerosis spinal collaboration patient culminate muscular atrophy longstanding commitment help try people impact community network share mobilise broad disease mind ask health system topic international perspective value care experience exchange patient organization year concert ieepo past year ieepo effort learn work signature roche offering help patient community integrate patient group share learning identify synergies feedback work market collaborate health topic healthcare accessible patient today centre stage roche world engage early systematically opportunity patient group tell business ensure thinking disease improve management shape feedback close patient group country outcome matter participate platform wwwieepocom survival relief symptom cure disease ieepo central vision past challenge regulatory patient partnership authority payer outcome measured medicine collaborative approach result require step consult roche rank corporate reputation patient community refine think peer group big pharma hope proactively get patient announce recognition communitys perspective answer testament vision partner right research question upfront patient willingness share trust responsibility research patient family drive year educate live cope carry rank base corporate reputation pharma report patientview independent organisation base ukbusiness ethic roche integrity underpin aspect business adriano treve join roche year ago trainee region iran saudi arabia bangladesh pakistan cyprus past year serve area head turkey russia iran central eastern europe central asia indian subcontinent adriano passionately believe integrity noncompliance universal vital roche cultural mindset preclude flexibility accommodate future success conduct business different culture long integrity preserve framework high professionalism example country small gift like compliance legal regulatory requirement chocolate respect business prerequisite licence operate interaction region vital sustainability reputation unacceptable advise team adriano future integrity extend simply ensure guide principle integrity motivation correct procedure follow suggest form normal ingrain culture local business practice likely alter basis engagement business code conduct define stand partner circumstance modest roche expect core value business gift normal remain token courage passion integrity adriano nature cultural variance licence explain confident manager excess colleague respond integrity empower express concern integrity leadership couple conscious trust colleague noncompliant behaviour effort foster behaviour team likely occur concern discuss crucial roche continue behave issue avoid approach consistent demonstrable personal integrity adriano extend team ensure consistently cultivate encourage directly work feel value area responsibility integrity able speak confidence drive mindset make ideal partner fear retaliation employee use world allow serve wide group patient anonymous roche group speakup line report compliant merely compliance concern intranet phone require right thing adriano support roche policy zero tolerance celebrate year anniversary adriano noncompliance draconian reflect future roche year come sound open supportive culture mean roche futurefit live opportunity unethical behaviour principle today guide success emerge say concern raise early year say important thing discuss openly action take continue attract talent ensure noncompliant behaviour avoid high calibre today people root code conduct apply organisation roche heartland make meaningful difference regardless geography culture zero tolerance patientsbusiness performance roche business performance key figure chf million group sale pharmaceutical sale diagnostic sale core operating profit core investment chf dividend growth rate report constant exchange rate cer average business performance roche diagnostic pharmaceutical employee operate divisional group corporate chugai research development site manufacture site pharmaceutical pharmaceutical diagnostic worldwide diagnostic worldwide treat roche medicine million patient model list essential medicine roche medicine number employee express fulltime equivalent roche group group sale rise chf new sale impact competition chf billion core operating profit increase biosimilar cancer medicine avastin chf reflect strong underlying herceptin mabtherarituxan slow business performance core eps grew expect combined chf billion sale chf swiss franc appreciation reduction second half year see currency affect result sign recovery covid pandemic express swiss franc compare constant exchange rate diagnostic division report strong sale growth chf billion division ifrs net income chf billion base business show strong momentum represent increase chf overall sale drive operating result total chf billion roche lead portfolio covid test contribute significantly december roche complete chf billion division overall sale repurchase roche share hold novartis restore roche strategic flexibility outlook retain operational scope action sale expect stable grow lowsingle digit constant exchange rate pharmaceutical division sale increase core earning share target grow chf billion strong demand newly low midsingle digit range constant launch medicine treat severe disease exchange rate include accretive effect hemlibra haemophilia ocrevus multiple recent share repurchase roche expect sclerosis tecentriq cancer evrysdi spinal increase dividend swiss franc muscular atrophy phesgo cancer drive growth medicine treatment covid roche anticipate sale covid medicine contribute sale growth ronapreve diagnostic decrease approximately highrisk covid patient actemra chf billion chf billion sale roactemra severe covid pneumonia loss biosimilar current year roughly chf billion exclude overall medicine launch effect group sale expect grow year contribute additional chf billion highsingle digit range sdg material topic longterm mindset growth rate report constant exchange rate cer average launch erivedge perjeta kadcyla gazyvagazyvaro esbriet cotellic alecensa tecentriq ocrevus hemlibra xofluza polivy rozlytrek phesgo enspryng evrysdi gavreto ronapreve susvimobusiness performance roche roche group pharmaceutical division sale chf million diagnostic division diagnostic diagnostic sale grew drive strong detection monitor donor screen momentum base business continue sexual health genomic high demand covid testing point care sale continue grow sale grow strongly world significantly sarscov rapid europe middle east africa emea antigen test main growth driver asiapacific north america especially emea region latin america customer area provide diagnostic division see strong sale growth solution immediately point care customer area emergency room medical practice directly patient include sarscov core lab sale increase rapid test blood gas electrolyte test immunodiagnostic business infectious cardiac test main contributor sale diabete care sale increase drive grow region strongly emea blood glucose monitor business asiapacific accuchek guide system customer area focus central lab customer area focus integrate provide diagnostic solution personalise diabetes management people area immunoassay clinical chemistry diabete healthcare professional custom biotech pathology lab sale increase molecular lab sale grew lead virology mainly growth advanced business delta variant continue push stain business growth covid testing highthroughput pcr test sale increase region lead customer area focus pathology labs north america asiapacific region provide diagnostic solution tissue biopsy companion diagnostic customer area focus molecular lab target diagnostic support specific provide diagnostic solution pathogen therapy decision patientbusiness performance roche sale customer area chf million core lab molecular lab point care diabetes care pathology lab pharmaceutical pharmaceutical division sale increase new return patient boost growth continue strong demand newly launch group generate strong sale medicine offset impact biosimilar perjeta approve chf billion herpositive breast cancer sale increase united states sale decrease high demand china early sale actemraroactemra hemlibra ocrevus metastatic breast cancer setting evrysdi tecentriq increase impact united states sale perjeta decline biosimilar covid pandemic affect certain patient switch kadcyla total growth expect launch phesgo europe sale grow growth recently tecentriq approve chf billion launch medicine compensate cancer immunotherapy impact biosimilar covid combination type cancer lung pandemic bladder breast liver cancer sale increase region notably japan primarily japan sale increase drive demand treatment hepatocellular strong demand new medicine carcinoma hcc sale higher drive compensate competition biosimilar new indication hcc firstline nonsmall government price cut cell lung cancer nsclc sale international region grow hemlibra approve chf billion china sale stable growth perjeta haemophilia factor viii alecensa heceptin offset impact inhibitor prophylactic treatment biosimilar exclude china sale increase administer subcutaneously weekly mainly drive new product sale partially week sale continue offset biosimilar competition strong uptake especially united states europe ocrevus approve chf billion relapse primary progressive form kadcyla approve chf billion multiple sclerosis twohour infusion herpositive breast cancer sale growth demand treatment indication drive usage kadcyla early remain strong mainly united states breast cancer set sale benefit patient pandemic certain negative impact switch new standard treatmentbusiness performance roche topselling pharmaceutical chf million ocrevus neuroscience perjeta oncology actemraroactemra immunology tecentriq oncology avastin oncology hemlibra haemophilia herceptin oncology mabtherarituxan oncologyimmunology kadcyla oncology xolair immunologycorporate governance roche corporate governance principle business activity focus sustainable governance roche complie value creation innovation management relevant corporate governance requirement culture conforming recognise standard particular applicable law swiss good corporate governance policy stock exchange swiss exchange directive transparent communication embody roche swiss code good practice corporate corporate governance principle build governance promulgate swiss business basis successful implementation federation economiesuisse company internal roche commitment serve stakeholder governance framework particularly article incorporation bylaw embody strong board director represent principle need ensure companys interest shareholder business manage supervise manner stakeholder highly skilled manager consistent good corporate governance act integrity extremely important include necessary check balance roche rank print annual report contain select link sustainable healthcare company roche website httpswwwrochecom pharmaceuticals index dow jones readers provide snapshot sustainability index djsi year company report date run recognition base indepth direct source consult analysis economic social environmental time uptodate information corporate performance djsi serve benchmark governance roche annual report investor integrate sustainability consideration cover single financial year end december portfolio sustainability core website contain information business practice award reflect permanent nature late roche news commitment run business way company article incorporation bylaw ethical responsible create longterm value curricula vitae current status stakeholder end term report date december year corporate governance report set year member board director structure process rule roche corporate executive committee publish take basis wellfunctione corporate website material topic compliance httpswwwrochecomaboutgovernancehtmcorporate governance roche annual general meeting annual general meeting board director board director board committees board committee chairmansnomination committee remuneration committee audit committee corporate governance sustainability committee corporate executive committee corporate executive committee ceo ceo ceo chief financial chief people roche group pharmaceutical diagnostic information officer officer enlarge corporate executive enlarge corporate executive committee committee gre pre partnering communication general counsel board director accordance art federal act structure composition remain statutory principle federal council committee show ordinance combat covid epidemic board director covid act art ordinance corporate executive committee measure combat coronavirus covid covid ordinance annual general march forthcome agm meeting agm roche holding ltd hold board director nominate chairman march physical participation remain member board director shareholder shareholder request reelection exception paul bulcke exercise right independent proxy prof hans clever paul bulcke testaris address question serve board director company writing decide stand reelection agm follow year agm roche holding ltd march tenure prof hans clevers join shareholder reelect christoph franz board director step chairman board director term position appoint new head year provide article incorporation roche pre effective march member enlarge corporate furthermore agm reelect andr hoffmann executive committee board director julie brown paul bulcke prof hans clevers propose jemilah mahmood currently jrg duschmal patrick frost anita hauser special advisor public health malaysia prof richard lifton bernard poussot prime minister election board severin schwan claudia suessmuth director agm dyckerhoff member board director term year provide article board director nominate incorporation christoph franz andr hoffmann prof richard lifton bernard poussot addition addition agm elect christoph franz patrick frost election remuneration andr hoffmann prof richard lifton committee agm bernard poussot member remuneration committee term year board director nominate testaris election independent proxy agm organising meeting immediately follow period conclusion agm board director determine ordinary agm shareholder board director board director board committees board committee chairmansnomination committee remuneration committee audit committee corporate governance sustainability committeecorporate governance roche board director member nationality france belgium female netherlands switzerland male austria germany year year year year year year year age tenure average tenure incl ceo year excl ceo incl dual citizen triple citizen calculate year election composition year birth elect board director christoph franz chairman andr hoffmann vicechairman representative shareholder group pool voting right jrg duschmal representative shareholder group pool voting right julie brown paul bulcke prof hans clevers patrick frost anita hauser prof richard lifton bernard poussot severin schwan claudia suessmuth dyckerhoff secretary annette luther board directors curricula vitae cvs member board director current member httpswwwrochecomaboutgovernanceboardofdirectorshtm member year httpswwwrochecomaboutgovernanceecbodformerhtm nformation cvs report date december year year httpswwwrochecomaboutgovernancearchivformercvshtm corporate governance sustainability committee audit committee remuneration committee chairmansnomination committee nonexecutive director executive director independent member board directors committee chairperson board directors committees andr hoffmann chair julie brown chair andr hoffmann chair christoph franz chair prof hans clevers jrg duschmal christoph franz andr hoffmann anita hauser paul bulcke prof richard lifton claudia suessmuth dyckerhoff patrick frost bernard poussotcorporate governance roche corporate executive committee membership corporate executive corporate executive committee listed committee remain unchanged board director corporate executive committee information member corporate executive committee enlarge corporate executive committee corporate executive committee ceo ceo ceo chief financial chief people roche group pharmaceutical diagnostic information officer officer enlarge corporate executive enlarge corporate executive committee committee gre pre partnering communication general counsel composition year birth position corporate executive committee severin schwan ceo roche group bill anderson ceo roche pharmaceutical thomas schinecker ceo roche diagnostic alan hippe chief financial information officer cristina wilbur chief people officer enlarge corporate aviv regev head genentech research executive committee early development gre william pao head roche pharma research early development pre james sabry global head pharma partner barbara schdler head group communications claudia bckstiegel general counsel secretary corporate perolof attinger executive committee statutory auditor kpmg klynveld peat marwick goerdeler reporting year roche holding ltd kpmg auditor charge ohn morris ian starkey mark baillache business year chief compliance officer pascale schmidt curricula vitae cvs member corporate executive committee enlarge corporate executive committee current member httpswwwrochecomaboutgovernanceexecutivecommitteehtm member year httpswwwrochecomaboutgovernanceecbodformerhtm information cvs report date december year year httpswwwrochecomaboutgovernancearchivformercvshtm group structure shareholder roche operate business organise business activity carry group division pharmaceutical diagnostic subsidiary associate company detail information roche holding ltd significant pharmaceutical division comprise subsidiary associate company include business segment roche pharmaceutical company list information domicile share chugai genentech capital equity interest list finance segment integrate roche report note roche group consolidated pharmaceutical financial statement list subsidiary associate transformation initiative diagnostic division replace previous major shareholder list finance business area structure business area report note roche group centralise point care solution molecular consolidated financial statement equity diagnostic tissue diagnostic diabetes care attributable roche shareholder relate new customer area sale present party page note follow customer area core lab molecular financial statement roche holding ltd lab point care diabetes care pathology lab significant shareholder addition detail finance report significant shareholder publish roche pharmaceutical incl genentech pharmaceutical chugai business area customer area centralise point care solution core lab diagnostic molecular lab molecular diagnostic point care tissue diagnostic pathology lab diabetes care diabetes care composition corporate governance roche relevant webpage link disclosure office exchange regulation andr hoffmann vicechairman board directors chairman remuneration committee board corporate governance sustainability committee member board chairmansnomination committee jrg duschmal member board director boards audit committee serve respective capacity board committee representative shareholder group pool voting right receive remuneration set forth remuneration report finance report note roche group consolidate financial statement relate party relationship exist shareholder pool voting right crossshareholding andr hoffmann chairman corporate governance sustainability committee remuneration committee jrg duschmal member audit committee exchange regulation httpswwwseragcomenresourcesnotificationsmarketparticipantssignificantshareholdershtml capital structure information roche capital structure provide earning liquidation proceed follow finance report note financial repayment share capital roche ne statement roche holding ltd right pertain thereto include additional detail contain article provision protect interest ne holder incorporation roche holding ltd describe article incorporation roche holding ltd movement recognise amount financial year detailed finance information debt instrument report note financial statement issue outstanding bond roche holding ltd provide finance report note roche group consolidate financial statement extraordinary general meeting hold debt november shareholders agree reduce company share capital information employee stock option provide chf chf finance report note roche chf cancellation group consolidated financial statement equity bearer share nominal value compensation plan include detailed chf repurchase information stocksettle stock appreciation company novartis hold pursuant right ssar plan restrict stock unit repurchase agreement date november rsus plan roche connect roche difference acquisition cost option plan nominal value bearer share cancel account reduction roche issue option apart employee voluntary reserve retain earning stock option describe finance report note roche group consolidated financial authorise conditional capital statement equity compensation plan option issue connection debt addition nonvoting equity instrument security nes issue bearer form form share capital option award employee confer voting right ne confer debt instrument issue right share participate available effect roche share capital httpswwwrochecomaboutgovernancearticleofincorporationhtmcorporate governance roche board director corporate executive committee information member board director independence definition base director member corporate definition swiss code good practice executive committee list page corporate governance economiesuisse member board director age limit complement specific precede criterion restriction term office httpswwwrochecomaboutgovernance boardofdirectorshtm curricula vitae cvs current member year principle governance principle body information include information delegation competence reservation power year election additional management group company position membership activity available executive body company include continuously update internet economic environmental social topic addition status cvs body principle internal organisation relevant reporting date december board director division authority year separately available responsibility board management remit board committee rule pursuant article para point vegv information control mechanism number permit activity board available board dealing corporate director corporate executive committee management govern bylaw member outline article incorporation roche holding ltd board director roche holding ltd organise ensure group conduct annual general meeting elect business responsibly focus member board director chairman longterm value creation end roche board director members board delegate certain responsibility remuneration committee annual basis committee composition election nominee vote chairperson december describe separately article incorporation page committee authority roche holding ltd minute responsibility define detail annual general meeting roche holding ltd bylaw board director hold march committee chair independent exception severin schwan director member board director office end member roche accord bylaw board director corporate executive committee serve board meeting convene executive capacity group subsidiary chairman present request financial year precede current member roche board meet year report period lack exist assess chairman performance meeting business connection group attend chairman chair group subsidiary independent roches board vicechairman httpswwwrochecomaboutgovernanceboardofdirectorshtm httpswwwrochecomaboutgovernanceexecutivecommitteehtm httpswwwrochecomaboutgovernancearticleofincorporationhtm httpswwwrochecomaboutgovernanceannualgeneralmeetingshtm httpswwwrochecomaboutgovernancearticleofincorporationhtm httpswwwrochecomaboutgovernancecommitteeshtm httpswwwrochecomaboutgovernancearticleofincorporationhtm board director board director board committees board committee chairmansnomination committee remuneration committee audit committee corporate governance sustainability committee corporate executive committee corporate executive committee ceo ceo ceo chief financial chief people roche group pharmaceutical diagnostic information officer officer management information system risk plan material risk mis board director regularly monitor deviation review regular informed important issue sale performance dialogue consolidate performance etc board access group risk report include target risk profile electronic information platform provide discuss corporate executive committee timely information board director approve group business board committee system plan material risk review board control set forth yearly basis effectiveness risk management process monitor group board director establish system risk advisory team overall process control continuously monitored regularly review external auditor audit committee corporate governance finding present audit committee sustainability committee board board detail risk management director consist follow element include risk factor risk management report operate financial risk risk policy risk management website management system financial risk management specifically describe roche group establish risk finance report management process cover entire system internal control financial reporting company system place identify finance report manage type risk potentially affect internal audit business include economic environmental group audit report general counsel social impact risk opportunity direct access give regular briefing stakeholder input board director audit committee corporate high governance body involve roche governance sustainability committee risk management policy set approach ongoing activity audit report chief accompany responsibility audit risk advisory executive attend audit pharmaceutical diagnostic division committee partly corporate governance global function conduct formal risk assessment sustainability committee meeting process year develop external auditor group audit independent httpswwwrochecomsustainabilityapproachriskmanagementhtm additional information provide finance report note roche group consolidate financial statement risk management corporate governance roche appraisal function evaluate review follow blackout period arewere effect group activity service board respectively director management annual audit plan yearly define focus area market blackout period access thirdparty management validate senior management approve audit december december committee roche group commit february february maintain high standard internal control april april april april worldwide operation management june july june july responsible assess business risk october october aspect operation implement october october effective efficient process control whilst ensure compliance internal external rule regulation conduct blackout period change chairman operational audits group audit determine board director circumstance warrant management response risk surround business process system evaluate roche employee involve preparation appropriateness completeness efficiency regular publicity event particular annual process control action plan halfyear report medium conference quarterly implement necessary change enhancement sale release access develop businessauditee potentially share price sensitive information track completion roche roche employee resident statutory auditor include citizens green card chief compliance officer compliance holder resident alien terminate officer subsidiary employee retiree fall safety health environmental protection category subject blackout department period irrespective relevant corporate sustainability committee information share price sensitive roche science ethic advisory group seag blackout period person issue relate genetic engineering shall relevant information confidential disclose noninsider member corporate executive outside roche include family member committee invite attend meeting buy sell trade equity security board director report person roche share nonvoting equity security agenda item concern ne option similar instrument situation warrant member enlarge derivative base thereon iii provide trade corporate executive committee recommendation thereon automatic execution invite attend board committee invite predefine periodic purchase order chairman board corporate executive roche connect programme subject committee member deliver report blackout period committee meeting elect commission independent expert report service addressee scope exception regard consultant blackout period refer roche group insider directive httpswwwrochecom year blackout period impose damjcrdfbdadccadaacabeb member board director engroupinsiderpolicypdf senior certain employee prohibit trading company stock httpswwwrochecomsustainabilityenvironmenthtm httpswwwrochecomsustainabilityhtm httpswwwrochecomresearchanddevelopmentwhowearehowweworkethicsinrdethicalconflictshtm julie brown chairwoman audit committee board director meet meeting ordinary meeting hour length include fullday meet extraordinary board meeting hour length hold connection major business transaction addition board go day trip european affiliate board committee meet follow chairmansnomination committee meeting approx hour remuneration committee meeting approx hour audit committee meeting approx hour corporate governance sustainability committee meeting approx hour board director regularly conduct assessment selfassessment assessment party electronic survey personal interview performance member corporate executive committee maximum ordinary notice period month changeofcontrol clause employment contract management contract fall scope subsection annex directive information relate corporate governance remuneration committee member recuse deliberation decision matter affect interest figure indicate actual length meeting include director extensive premeete preparation postmeete followup activitiescorporate governance roche attendance board board committee meeting corporate chairmans governance nomination remuneration audit sustainability board committee committee committee committee number meeting franz hoffmann duschmal brown bulcke clevers frost hauser lifton poussot schwan suessmuth dyckerhoff member committee remuneration shareholding loan detail remuneration shareholding rule aoi loan content method determine content board cec compensation shareholding programme rule principle basic principle element compensation applicable performance shareholding programme serve related pay member board director corporate rule principle executive committee description allocation equity security authority procedure determine convertible right option set forth separate remuneration report additional page finance report payment member note roche group consolidated executive committee financial statement equity attributable roche appoint vote shareholder relate party page pay annual general list note financial meeting shareholder statement roche holding ltd board rule loan credit facility executive shareholding postemployment benefit rule vote pay follow rule remuneration shareholding agm loan board director board corporate executive committee cec set forth article incorporation aoi httpswwwrochecomaboutgovernancearticleofincorporationhtmcorporate governance roche participatory right shareholder participatory right shareholder article incorporation define roche article incorporation shareholder represent share nominal roche share issue bearer value chf million request restriction admission annual general placement item agenda annual meeting exception share general meeting later deposit specify period day date meeting date meeting admittance card issue shareholder provide rule issue instruction article incorporation shareholder independent proxy rule electronic elect represent party participation annual general meeting annual general meeting lay correspond invitation annual general meeting regulate article incorporation contain restriction article incorporation exercise voting right quorum requirement stipulate conformity swiss code obligation change control defensive measure article incorporation contain provision nonvoting equity security terminate mandatory bid rule swiss law apply event acquisition vest period restriction preexist award changeofcontrol clause remove option component remuneration base roche exercise immediately httpswwwrochecomaboutgovernancearticleofincorporationhtm relationship statutory auditor annual general meeting roche holding ltd potential nonaudit service engagement march shareholder vote review policy authority appoint kpmg kpmg statutory auditor proceed give base exist legal requirement auditor direct access audit swiss code obligation article concern committee chair head maximum term office seven year group audit discuss relevant issue auditor charge mark baillache auditor charge business year report statutory auditor information long auditor charge consolidated financial statement serve capacity provide financial statement find page statutory auditor participate respectively finance report audit committee meeting prepare write oral report result audits kpmg receive follow remuneration audit committee oversee assess service statutory auditor roche holding ltd auditor make recommendation auditor roche company board information authority include chugai responsibility audit committee article bylaw statutory auditor participate meeting audit millions chf committee auditing service auditrelate service performance kpmg assess base assurance different element affiliate survey nonstatutory audits evaluate service level country level tax service interview roche key stakeholder service selfevaluation kpmg internal process total ensure compliance federal audit oversight authority faoa audit committee guide audit fee review head group audit kpmgs independence ensure limit approve audit committee year kpmg provide certain nonaudit service take consideration change roche furthermore permit service exceed business change financial report total audit fee explicitly audit standard regulation rewieve approve audit committee company formal policy govern statutory auditor elect year engagement statutory auditor nonaudit annual general meeting service limit certain permit service agree audit committee auditing service provide legally require httpswwwrochecomaboutgovernancearticleofincorporationhtmcorporate governance roche auditrelated service include assurance tax service include service respect accounting service provide auditor compliance tax return tax advice necessarily provide statutory service relate audit tax auditor service legal requirement include attestation service include advice relate process service comfort letter consultation improvement regulation training relationship independent proxy testaris serve board director nominate testaris independent proxy annual general election independent proxy annual general meeting march shareholder meeting period elect testaris independent proxy conclusion ordinary annual general period conclusion meeting shareholder ordinary annual general meeting shareholders testaris pay rule issue instruction independent service annual general meeting proxy rule electronic participation extraordinary geneneral meeting annual general meeting lay november accord expenditure totalling correspond invitation annual general meeting chf chf regulate article incorporation information policy provide article incorporation presentation analyst investor conference corporate notice publish swiss available internet publication official gazette commerce daily available newspaper designate board director httpswwwrochecompublicationshtm basler zeitung finanz und wirtschaft lagefi order email temps neue zrcher zeitung baselwarehouseservicesrochecom fax roche report halfyear fullyear result business report publish print andor online contact address investor relation format medium event addition detail hoffmannla roche ltd investor relation firstquarter month sale figure group finance basel switzerland publish year april october tel current list publication date available fax internet additional information include detail relevant information document include specific contact person available medium release investor update internet httpswwwrochecomaboutgovernancearticleofincorporationhtm httpswwwrochecommediahtm httpswwwrochecominvestorshtm httpswwwrochecominvestorscontactshtmcorporate governance roche chief compliance officer compliance officer network chief compliance officer compliance line compliance tool furthermore serve officer network commit ensure platform idea suggestion concern roche group code conduct consistently document comply roche group chief compliance officer serve contact addition roche establish business ethic person shareholder employee business incident report beir system enable partner customer supplier general chief compliance officer capture track public issue relate implementation monitor allege violation initial report compliance code local compliance officer group internal investigation department resolution employee party aware violation roche group code conduct business ethic incident record bring attention manager system group internal investigation supervisor local compliance officer department regionallocal management report chief compliance officer receive specific concrete information pascale schmidt allege violation roche group code email pascaleschmidtrochecom conduct certain predefine category tel disclosure corporate governance sustainability treat confidentially addition employee committee audit committee board anonymously report irregularity complaint director inform substantial violation mother tongue speakup line case management corrective action take question uncertaintie interpretation roche group code conduct chief compliance officer report reference document employee reach general counsel submit regular report line manager local compliance officer corporate governance sustainability chief compliance officer contact committee need audit committee roche group code conduct help advice board director nonapplicabilitynegative disclosure expressly note information negative declaration provide swis contain mention non exchange corporate governance directive applicable omission construe commentary thereto httpswwwrochecomaboutgovernancecodeofconducthtm httpswwwrochecomaboutgovernancecodeofconductcomplianceofficerhtm httpswwwrochecomaboutgovernancecodeofconducthtmremuneration report roche remuneration report principle roche innovative agile company performance successbase success depends substantially expertise transparent compensation structure ensure motivation performance employee compensation package competitive conviction form basis compensation structure individual component policy regularly benchmarke base relevant swiss european international market criterion roche aim remunerate employee fairly remuneration guideline underlie transparently line market condition principle subject regular outside enable participate appropriately comparison company success pursue goal provide equitable competitive performance compensation policy factor base resultsoriente compensation safeguard roche future success key element corporate culture offer strive balanced mix fix variable employee condition compensation component gear good possible contribution share corporate employee position management responsibility goal improve healthcare patient include sound sustainabilityoriente firstly variable component intend value system base integrity courage create additional financial incentive achieve passion time decentralise corporate goal innovation management approach play major role consistently high level increase value wide scope individual decisionmake company create stakeholder respectful interaction openness diversity wide group secondly order allow employee range training development opportunity manager participate company business attractive working environment unidimensional success adequate compensation measure diminishment question remuneration key objective incentivise annual fall far short bonus payment longterm securitiesbase programme roche commit fair performancebase resultsoriente compensation policy link global company like roche market employee interest competitive remuneration play key role stakeholder group compensation policy httpswwwrochecomcareersforemployeesrewardshtm sound value system httpswwwrochecomcareersforemployeeslivingourvalueshtmremuneration report roche remuneration decision process approval framework overview present remuneration year remuneration committee roche committee decide correspond board director decide remuneration compensation right decision board member member group decision right reserve remuneration corporate executive committee committee member chairman group ceo member group corporate executive committee remuneration decision process approval framework beneficiary remuneration board director bod corporate executive decision approval component chairman committee cec incl ceo roche group base pay remuneration bonus stocksettle stock remuneration committee annual general meeting appreciation right ssar restrict stock unit rsus pension remuneration committee track market datum total aggregate amount salary lead global pharmaceutical base decision submit company major swiss company general meeting approval implement report finding board external ordinance excessive compensation consulting firm pricewaterhousecooper pwc list jointstock company verordnung gegen assist remuneration committee roche bermssige vergtungen bei brsenkotierten perform market comparison advise aktiengesellschaften vegv general meeting pwc award additional mandate shall vote annually bind effect roche group information remuneration approval remuneration board committee remit power procedure director resolve board director make remuneration decision find corporate executive committee detail bylaw roche board director article incorporation outline section principle govern specific remuneration component peer set abbott laboratories abbvie amgen astrazeneca bristolmyers squibb danaher eli lilly glaxosmithkline johnson johnson medtronic merck novartis novo nordisk pfizer sanofi abb alcon credit suisse holcim lonza nestl richemont ubs zurich httpswwwrochecomaboutgovernancearticleofincorporationhtm httpswwwrochecomaboutgovernancearticleofincorporationhtm abbott laboratories abbvie amgen peer set astrazeneca bristolmyers squibb abb danaher alcon eli lilly credit suisse glaxosmithkline holcim johnson johnson lonza medtronic nestl roche merck richemont novartis ubs novo nordisk zurich pfizer sanofi peer set market comparison company salary assessment pharma peer set major swiss company procedure submit total board retrospective approval executive remuneration shareholder total aggregate bonus amount corporate approval annual general meeting executive committee chairman year annual general meeting agm board director financial year end shareholder approve total remuneration submit retrospectively ordinary board director corporate agm separate bind approval executive committee decide board director remuneration committee prospective approval board director respectively board executive aggregate remuneration submit prospectively accord approval agm agm separate bind approval roche commit obtain separate period ordinary agm bind shareholder approval total remuneration pay board director corporate executive committee followsremuneration report roche andr hoffmann chairman remuneration committee approval total remuneration annual general meeting agm financial year financial year retrospective bonus chairman board director bod bonus financial year total cec corporate executive committee cec include ceo roche group bonus bonus financial year total prospective bod base pay remuneration board director bod include chairman aggregate total remuneration agm agm base pay remuneration cec corporate executive committee cec include ceo roche group base pay aggregate total remuneration agm agm ssar base pay rsus stocksettle stock appreciation right ssar indirect benefit restrict stock unit rsus indirect benefit agm agm agm remuneration component overview remuneration element performance nonfinancial success remuneration member board align interest roche employee director corporate executive committee shareholder societal environmental compose follow element objective take account fix base salary complement lti remuneration component intend annual variable bonus shortterm incentive sustainably homogenously longterm sti perennial remuneration element orient perspective align management interest ssar rsus longterm incentive lti shareholders holder non vote equity security participate remuneration component link manager additional incentive achieve employee performance company financial sustainable shareholder value growth composition remuneration board director corporate executive committee board director corporate executive committee annual remuneration element description bod ceo roche group cec base pay monthly payment quarterly remuneration payment bonus annual payment year year cash block nonvoting block nonvoting equity security equity security andor share andor share pension etc perennial remuneration element stocksettle stock year appreciation right additionally ssar block nonvoting equity security exercise restrict stock year unit rsus block nonvoting equity security httpswwwrochecominvestorssustainabilitydownloadcenterperformancehtm httpswwwrochecomsustainabilityenvironmentourshegoalsandperformancehtmremuneration report roche lti corporate executive committee expiration period align newly enlarge corporate executive issue ssar rsus unlike committee compose ssar participant programme member rsus base exist individual corporate executive committee target value total lti corporate executive choice determine mix rsus ssar committee member base pay fouryear cliff vest measured january year vest corporate executive committee lti mix ssarsrsus fix base calculation vest period cliff vest expiration period base individual target ssar value total lti year year year corporate executive committee member base pay rsus measure january year year year remain participant ssar offer level choice empower participant rsus programme offer yearly basis engage fully total reward enable choice combination determine mix well understand critical element restrict stock unit rsus stocksettle compensation increase value stock appreciation right ssar option programme instead ssar country follow option available attractively design roche longterm incentive programme enable roche attract choice choice choice motivate retain good talent ssar ssar ssar align company longterm success rsus rsus rsus fix base salary indirect benefit employer contribution pension insurance contribution roche roche connect sti remuneration tax consulting service bonus component expense allowance lti stocksettle stock appreciation right restrict stock unit children school cost foreign tax obligation variable longterm ahvivalv employer contribution social security beneficial part base pay fix bonus variable base pay cash payment determine bonus annually award individual position base salary market datum contribution value creation business year lead global pharmaceutical company mean incentive strive outstanding footnote major swiss company result create new business opportunity footnote reflect individual ability bonus amount link group divisional experience performance time pay core profit sale growth constant exchange adjustment likewise link individual rate operate profit capital charge opac performance account prevail base core operating profit core earning market condition company overall share nonvoting equity security ne growth financial situation constant exchange rate product development pipeline diversity employee manager remuneration committee make review environmental goal additionally link final decision individual base pay pay achievement measurable qualitative chairman board director individual functional performance objective member corporate executive committee competitive reason roche disclose remuneration member individual performance objective member board corporate executive committee chairman httpswwwrochecomcareersforemployeesdiversityhtm httpswwwrochecomsustainabilityenvironmentourshegoalsandperformancehtm goal roche group httpswwwrochecomdamjcrbcfadadaffeedenshegoalscommunicationpdfremuneration report roche december end reporting year restrict stock unit rsus longterm january follow reporting year proportion restrict stock unit rsus remuneration committee decide bonus member corporate executive committee amount payable chairman total lti base individual board member corporate executive target value total lti corporate executive committee respect relevant reporting year committee member base pay base performance aforementione measure january year objective time remuneration committee decide form bonus rsus contain right receive nonvoting equity award cash payment andor block security andor share fouryear vest applicable nonvoting equity security andor period plus value adjustment share equivalent sum dividend pay vest period attributable number remuneration committee use discretion nonvoting equity security andor share appropriately weight criterion individual award grant bonus allocation vested recipient corporate executive committee year total employee result nonvoting equity eligible bonus roche bonus program security andor share remain block year stocksettle stock appreciation right ssar longterm rsu award allocate individually ssar proportion lti corporate corporate executive committee executive committee base remuneration committee discretion individual target value total lti corporate executive committee member rsus serve remuneration component base pay measure january year eligible roche employee ssar entitle holder benefit financially indirect benefit increase value roche nonvoting show ceo roche group equity security grant date chairman respectively member exercise date ssar grant vest corporate executive committee additionally year exercise receive indirect benefit pension fund insurance year grant date unexercised contribution roche connect payment foreign ssar lapse compensation tax obligation tax consulting service fair value ssar calculate annual expense allowance show grant date trinomial model american individual member corporate executive option detail committee receive payment family child education allowance school cost ssar corporate executive committee child allocate individually remuneration committee discretion total employee receive ssar weight fix variable longterm remuneration component target percentage total remuneration chairman board director corporate executive committee include ceo roche group fix variable longterm variable longterm remuneration pay member corporate executive committee range total compensation ratio variable remuneration component relative fix base pay corporate executive committee ratio variable remuneration component bonus ssar rsus relative value fix base pay lti longterm sti variable total criterion bonus ssar total lti rsus total lti individual target value minimum maximum performance criterion group objective group divisional business value development value development performance individual objective consider determined determined core profit sale growth constant exchange rate performance performance plus operating profit capital charge opac base nes grant value adjustment core operating profit core earning share dividend nonvoting equity security ne growth constant ne grant exchange rate product development pipeline diversity employee manager environmental goal split group objective individual objective weighting criterion remuneration committee discretion decision objective applicable assess consideration performance competitor macroeconomic development base exist individual target value total lti corporate executive committee member base pay measure january year detail refer follow section remuneration report finance report note roche group consolidate financial statement relate party note financial statement roche holding ltd board executive shareholding remuneration board director resolution approval board director table remuneration chairman board board activity roche pay employer director member board director contribution totalling chf social decide remuneration committee security agency member board discretion take account market comparison director legally require contribution separately state chairman board remuneration form cash payment director annually track market datum director pay lead global pharmaceutical basic remuneration board director company footnote major swiss exclude chairman remain unchanged company footnote assist consultancy pwc exception chairman board previous year board director bonus form block share director separately submit total aggregate severin schwan executive member bonus chairman board director board member board director general meeting financial year award share nonvoting equity retrospective bind approval security ssar maximum amount total aggregate loan credit grant remuneration board director member board director period ordinary general meeting ordinary general meeting capacity member chugai separately table previous international council cic chugai year general meeting prospective bind pharmaceutical ltd andr hoffmann approval receive honoraria amount total usd chf remuneration member board director advisory service member board director genentech scientific resource board receive remuneration additional compensation prof richard lifton prof hans clevers form quarterly fix cash payment receive honoraria amount total show remuneration member usd chf list member position committee membership chairmanship detidua remuneration report roche remuneration member board director chf additional remuneration additional special additional basic remuneration committee memberschair remuneration bvg cost total remuneration franz chairman total remuneration pay chairman board director hoffmann vicechairman brown bulcke clever duschmal frost hauser lifton poussot schwan high total remuneration pay severin schwan member corporate executive committee remuneration receive primary function ceo roche group reflect total remuneration corporate executive committee suessmuth dyckerhoff total cost provision swiss federal occupational old age survivor invalidity pension act bvg accordance minimum requirement insurance benefit bvg half cost member board director subject compulsory insurance bear company exception member chairmans committee chairman vicechairman board member receive chf year committee serve chf year committee chair remuneration serve vicechairman board additionally employer contribution ahvivalv totalling chf include chairman pay form remuneration detidua remuneration member board director chf additional remuneration additional special basic remuneration committee memberschair remuneration total remuneration franz chairman total remuneration pay chairman board director hoffmann vicechairman brown bulcke clevers duschmal march frost march hauser lifton poussot schwan high total remuneration pay severin schwan member corporate executive committee remuneration receive primary function ceo roche group reflect total remuneration corporate executive committee suessmuth dyckerhoff bell march oeri march total exception member chairmans committee chairman vicechairman board member receive chf year committee serve chf year committee chair remuneration serve vicechairman board prorate remuneration period march december prorate remuneration period january march additionally employer contribution ahvivalv totalling chf include chairman pay form remuneration total remuneration pay chairman year payable march board director shareholder bind vote ordinary chairman christoph franz receive total annual general meeting agm remuneration show remuneration committee bonus proposal chairman total remuneration contain adopt late respect total remuneration board director financial year form share block detidua remuneration report roche total remuneration pay board addition sir john bell social security director contribution amount chf calendar year member pay foreign state social security institution board director receive remuneration include bonus employer contribution additional remuneration pay social security beneficial part totalling chf chf exclude board remuneration subject approval additional employer contribution pay annual general meeting social security totalling chf chf include contribution submission chairman total foreign authority amount chf aggregate bonus bind vote annual general meeting remuneration pay member remuneration chairman board board director director include bonus award chf member board director franz form share block year show humer receive fee amount table section total remuneration pay total usd chf serve chairman board directors board member chugai international council cic director submit remuneration committee chugai pharmaceutical ltd member bonus proposal adopt late board director william burns chairman board christoph franz respect receive fee amount total usd financial year payable march chf capacity member exclude legally require employer contribution chugai international council cic chugai ahvivalv shareholder bind vote pharmaceutical ltd ordinary annual general meeting detidua detidua total remuneration pay chairman board director chf base salary cash tax equalisation pension fund correction bonus subject approval annual general meeting pension fund insurance annual expense allowance tax social security include employer contribution social security beneficial part total applicable form share block year calculation number share base price date transfer march respectively approval agm agm respectively calculation value consideration reduction value block period year reduce market value submit shareholder approval agm approve agm respectively agree reduction pension fund contribution reach age dditionally employer contribution ahvivalv chf chf pay form remuneration detidua remuneration report roche retrospective approval chairman total aggregate bonus chf proposal agm agm agm aggregate aggregate aggregate financial year financial year financial year total aggregate proposal approval approve agm exclude legally require employer contribution ahvivalv bonus award form share block year calculation number share base price date transfer march march march respectively approval agm agm agm respectively calculation value consideration reduction value block period year reduce market value submit shareholder approval agm approve agm agm respectively submission board total aggregate severin schwans remuneration show future remuneration bind shareholder receive function ceo vote roche group member corporate board director propose executive committee include ordinary agm approve board remuneration totalling corporate executive committee chf exclude legally total remuneration require employer contribution ahvivalv exclude bonus period end ordinary agm prospective approval board total aggregate future remuneration chf proposal agm agm agm aggregate aggregate aggregate period period period agm agm agm agm agm agm total aggregate proposal approval approve agm exclude legally require employer contribution ahvivalv exclude bonus reconciliation report exclude bonus period end remuneration shareholder ordinary agm approve remuneration member board director comparison ordinary agm ordinary agm approve board ordinary agm actual remuneration remuneration totalling amount chf exclude legally chf exclude legally require require employer contribution ahvivalv employer contribution ahvivalv exclude bonus prospectively approve total remuneration member board director comparison actual total payment chf total remuneration total remuneration total remuneration period period period agm agm agm agm agm agm maximum total remuneration approve agm actual total remuneration pay calculation end period approve limit calculation end period yes yes exclude legally require employer contribution ahvivalv exclude bonus security holding statement relate party director andr hoffmann jrg duschmal note financial statement member founder family roche holding ltd significant shareholder closely associate belong addition december contractually bind shareholder group december respectively pool voting right end member board director person group hold share issue closely associate hold roche share share detailed information group nonvoting equity security nes american find finance report note depositary receipt adrs show roche group consolidated financial table security holding security holding share nes december december nonvoting nonvoting close equity close relative equity relative security security security security share ne holding number share ne holding number number number numbertype type number number numbertype type board director franz hoffmann brown bulcke clevers duschmal frost hauser ne nes lifton adr adrs poussot schwan security holding security holding corporate executive committee corporate executive committee suessmuth dyckerhoff total ne adr ne adrs share hold shareholder group pool voting right list jointly hold close relative roche adr american depositary receipt list otcqx httpswwwotcmarketscomstockrhhbyquote international premier symbol rhhby isin trade usd adr represent underlying nesremuneration report roche remuneration corporate executive committee resolution approval remuneration member remuneration member corporate corporate executive committee executive committee decide general provision assign authority remuneration committee discretion taking decision corporate executive committee account market comparison remuneration remuneration committee board director outline previous year board remuneration decision process approval director separately submit total aggregate framework bonus corporate executive committee general meeting financial year member corporate executive retrospective bind approval committee receive remuneration work show remuneration maximum amount total ceo roche group severin schwan aggregate remuneration corporate explain detail executive committee period ordinary general meeting ordinary general meeting table previous year general meeting prospective bind approval high total remuneration pay high total remuneration pay member severin schwan member corporate executive committee corporate executive committee include total pay corporate severin schwan executive member board executive committee total remuneration director receive remuneration primary pay member corporate executive function ceo roche group reflect committee high total remuneration pay severin schwan member corporate executive committee chf base salary bonus subject approval total aggregate bonus corporate executive committee annual general meeting ssar rsus roche connect pension fund insurance payment incl expense allowance tax consulting service total detailed calculation remuneration annual report light overall economic impact covid pandemic severin schwan waive chf contractual base salary share block year calculation number share base share price date transfer march approval agm sars number grant value accord trinomial model american option chf trinomial model american option value describe stocksettle stock appreciation right ssar member corporate executive committee ssar block year exercise whilst exercise result ne automatically block additional year calculation value nonvoting equity security consideration reduction value additional block period year reduce market value ssar number grant value accord trinomial model american option chf trinomial model american option value describe stocksettle stock appreciation right ssar member corporate executive committee ssar block year exercise whilst exercise result ne automatically block additional year calculation value nonvoting equity security consideration reduction value additional block period year reduce market value calculation rsus value number rsus multiply grant value chf ne closing price grant date march rsu calculation rsus value number rsus multiply grant value chf ne closing price grant date march rsu include annual expense allowance chf payment tax consulting service chf chf family child education allowance chf chf additionally employer contribution ahvivalv chf chf pay form remuneration calculation value nonvoting equity security share consideration reduction value block period year reduce market value include employer contribution social security beneficial part detidua base pay member corporate executive committee base pay chf anderson hippe schinecker wilbur total bonus member bonus bring forward bind corporate executive committee vote annual general meeting remuneration committee board director determine corporate executive severin schwan members committee member bonus base corporate executive committee receive performance agree objective bonus cash payment severin remuneration committee use discretion schwan receive bonus form roche appropriately weight criterion share block year bonus allocation total aggregate bonus payment march bonus chf subject approval total aggregate bonus corporate executive committee annual general meeting anderson hippe schinecker wilbur total detidua detidua remuneration report roche stocksettle stock appreciation base exist individual target right ssar member value total lti corporate executive corporate executive committee committee member base pay ssar corporate executive committee measure january year allocate individually remuneration committee discretion ssar show fair value ssar calculate ssar table entitle holder grant date trinomial model american benefit financially increase value option trinomial model effective roche nonvoting equity security nes method valuation american option grant date exercise date strike consider possibility exercise option price ssar term multiyear time prior maturity call american option plan closing price roche ne grant compare european option date ssar vest previously allow exercise maturity date grant ssar year grant date vest ssar exercise converted number ssar strike price expiry ne previously grant ssar date grant value ssar show seven year grant date unexercised ssar ssar table lapse compensation number ssar calculate time issue enter value table ssar proportion lti corporate executive committee restrict stock unit rsus rsus contain right receive nonvoting equity member corporate security andor share newly executive committee define fouryear vest period plus value proportion restrict stock unit adjustment equivalent rsus member corporate executive sum dividend pay vest period committee total lti base attributable number nonvoting equity exist individual target value total security andor share individual lti corporate executive committee member award grant vested base pay measure january recipient corporate executive committee year rsu award allocate individually year result non corporate executive committee voting equity security andor share remain remuneration committee discretion block year information trinomial model american option refer boyle phelim lattice framework option price state variable journal financial quantitative analysis volume issue mar httpswwwrochecomdamjcraaacbfa bcbeacentrinomialmodelpdf detidua stocksettle stock appreciation right ssar grant value grant value number ssar chf value chf number ssar chf value chf anderson hippe schinecker wilbur total price chf expiry date price chf expiry date detidua restrict stock unit rsus value grant value grant number chf value chf number chf value chf anderson hippe schinecker wilbur total calculation value consideration reduction value additional block period year reduce market value calculation value consideration reduction value additional block period year reduce market value indirect benefit member roche nonvoting equity security nes corporate executive committee equal annual salary employer contribution social discount ne purchase plan security scheme pension plan groupwide subject hold period year employee stock purchase plan roche connect switzerland respect member corporate executive committee show indirect benefit addition member corporate executive employer contribution table committee receive annual expense allowance table member payment foreign tax obligation tax consulting service show roche connect voluntary stock purchase table plan offer employee opportunity buy detidua remuneration report roche indirect benefit employer contribution chf payment payment annual tax tax annual tax tax pension fund expense roche consulting pension fund expense roche consulting insurance allowance connect service insurance allowance connect service anderson hippe schinecker wilbur total include employer contribution social security beneficial partsdetidua detidua detidua remuneration loan member contribution social security beneficial part corporate executive committee totalling chf chf excl ceo roche group exclude additional employer contribution meet legal contractual obligation pay ahvivalv totalling chf roche pay total chf individual chf form member corporate executive committee remuneration family child education allowance children school cost additional remuneration abovementione payment pay current aforementioned additional payment member corporate executive include total remuneration member committee corporate executive committee corporate executive committee loan credit grant remuneration subject approval member corporate executive annual general meeting committee submission corporate executive maximum regular period notice member committee total aggregate bonus corporate executive committee month bind vote annual general meeting changeofcontrol clause board director propose award employment contract member corporate executive committee bonus severin schwan form roche remuneration member share block year corporate executive committee member corporate executive total chf pay gottlieb keller committee cash payment totalling chf respect total remuneration pay member financial year chf exclude corporate executive committee legally require employer contribution calendar year member social security agency submit corporate executive committee receive propose total ordinary annual remuneration include bonus employer general meeting agm bind vote retrospective approval member corporate executive committee total aggregate bonus chf proposal agm agm agm aggregate aggregate aggregate financial year financial year financial year total aggregate proposal approval approve agm exclude legally require employer contribution ahvivalvremuneration report roche submission corporate executive compose base pay longterm incentive committee total future aggregate ssar calculate grant value remuneration bind shareholder vote consider reduction value board director propose block period applicable rsus ordinary agm approve remuneration calculated time reservation corporate executive committee totalling nonvoting equity security share chf exclude legally consider reduction value block require employer contribution ahvivalv period pension benefit exclude legally exclude bonus period end require employer contribution ahvivalv ordinary agm contribution expense payment foreign tax obligation tax consulting corporate executive service roche connect committee total future aggregate remuneration prospective approval member corporate executive committee total future aggregate remuneration chf proposal agm agm agm aggregate aggregate aggregate period period period agm agm agm agm agm agm total aggregate proposal approval approve agm exclude legally require employer contribution ahvivalv exclude bonus reconciliation report exclude bonus period end remuneration shareholder ordinary agm prospectively approve remuneration member corporate executive comparison ordinary agm committee ordinary agm remuneration amount ordinary agm approve remuneration chf exclude legally require corporate executive committee totalling employer contribution ahvivalv chf exclude legally exclude bonus require employer contribution ahvivalv prospectively approve total remuneration member corporate executive committee comparison actual total remuneration effect chf period period period agm agm agm agm agm agm maximum total remuneration prospectively approve agm actual total remuneration realise total remuneration calculate end calculation end corresponding agmagm period period agm agm approve limit calculation end period agm agm yes yes additional pay new member corporate executive committee approval agm approved total exclude legally require employer contribution ahvivalv exclude bonus clawback accord ssar plan rule addition applicable statutory provision misconduct participant include roche longterm incentive plan include option inter alia partially reclaim distribute compensation result special circumstance clawback activity lead disciplinary action repeat willful failure perform duty employee voluntarily serve notice reasonably assign roche termination employment ssar violation law public regulation rsus unvested date commission crime termination employment lapse immediately gross negligence willful misconduct compensation employment engage conduct bring disgrace termination employment result disrepute roche andor subsidiary misconduct ssar rsus grant violation roche directive outstanding vest unvested guideline relate business conduct shall lapse immediately compensationremuneration report roche guideline security holding end retain holding board director decide long serve corporate executive ceo roche group member committee exception bill anderson corporate executive committee acquire thomas schinecker join share andor nes equivalent annual corporate executive committee base salary ceo roche group fulfil requirement end equivalent annual base salary member corporate annual base salary respectively executive committee fulfil requirement type security value acquire ceo roche group share andor nes annual base salary member corporate executive committee share andor nes annual base salary security holding associate held security show december december follow table share nonvoting respectively member corporate equity security ne ssar restrict executive committee person closely stock unit rsus share nonvoting equity security nes december december close relative close relative share ne security holding share ne security holding number number numbertype number number numbertype corporate executive committee share ne share nes schwan anderson hippe schinecker wilbur total ssar number ssar hold december corporate executive committee schwan anderson hippe schinecker wilbur total price chf market price ne december chf expiry date grant value ssar chf trinomial model american option value accord correspond annual report restrict stock unit rsus number rsus hold december corporate executive committee schwan anderson hippe schinecker wilbur total grant value rsu chf chf chf ne closing price grant date ne closing price grant date ne closing price grant date march march march statutory auditor report roche general meeting roche holding ltd basel audit accompany assurance remuneration remuneration report roche holding ltd report complie swiss law article year end december ordinance audit limited information accord article ordinance audit involve perform procedure excessive compensation list jointstock obtain audit evidence disclosure company ordinance contain remuneration report regard section mark audit grey compensation loan credit accordance line include respective footnote article ordinance page remuneration report procedure select depend auditor judgement include assessment risk responsibility board director material misstatement remuneration board director responsible report fraud error audit preparation overall fair presentation include evaluate reasonableness remuneration report accordance method apply value component swiss law ordinance board remuneration assess overall director responsible designing presentation remuneration report remuneration system define individual remuneration package believe audit evidence obtain sufficient appropriate provide auditor responsibility basis opinion responsibility express opinion accompany remuneration report opinion conduct audit accordance swiss opinion remuneration report auditing standard standard require year end december roche comply ethical requirement hold ltd complie swiss law article plan perform audit obtain reasonable ordinance kpmg mark baillache marc ziegler license audit expert license audit expert auditor charge basel february kpmg viaduktstrasse box basel kpmg subsidiary kpmg holding member kpmg network independent firm affiliate kpmg international cooperative kpmg international swiss legal entity right reserve independent limited assurance report nonfinancial report corporate governance sustainability committee roche holding ltd basel engage corporate key figure relation contribution governance sustainability committee switzerland disclose perform assurance procedure provide limited report assurance nonfinancial report roche holding ltd consolidated subsidiary criterion roche year end december specify nonfinancial information disclose annual report report prepare corporate governance prepare accordance suitable sustainability committee roche base criterion select roche follow criterion suitable criterion roche materiality determination process scope subject matter group level base gri standard assurance engagement relate limited publish october global level assurance specify nonfinancial reporting initiative gri information year end december roche group internal nonfinancial reporting disclose annual report guideline base responsible care health safety environmental protection follow specify datum information report guideline publish european publish report scope chemical industry council cefic gri limited assurance engagement standard publish october materiality determination process roche global reporting initiative gri group level according requirement define guideline safety security gri standard disclose page health environmental people report contribution key figure sustainability design sustainability risk risk opportunity internally gather opportunity determination process base collate aggregate group level activity disclose roche group guideline grant donation paragraph risk management report sponsorship gsd data collection process correctness follow consolidate disclose website httpswwwrochecom key figure damjcrfffeadbaccaddbcc people key figure graph engrantsdonationssponsorshipprocesspdf report publish january safety security health environmental protection key figure include inherent limitation greenhouse gas emission scope accuracy completeness specify scope result business flight nonfinancial information subject inherent table graph page limitation give nature method report determine calculate estimate datum pricewaterhousecooper birchstrasse postfach zurich telephone telefax wwwpwcch pricewaterhousecoopers member global pricewaterhousecooper network firm separate independent legal entityindependent limited assurance report roche addition ghg quantification subject pricewaterhousecoopers apply international inherent uncertainty incomplete standard quality control accordingly scientific knowledge determine emission maintain comprehensive system quality factor value need combine control include document policy emission different gas assurance procedure compliance ethical report read connection requirement professional standard publicly available individual roche applicable legal regulatory requirement group guideline roche definition procedure thirdparty practitioner responsibility guideline present specify responsibility perform assurance nonfinancial information performance engagement express limited assurance conclusion specify nonfinancial responsibility corporate governance information roche report sustainability committee conduct engagement accordance corporate governance sustainability international standard assurance engagement committee roche holding ltd responsible isae revise assurance engagement selection application suitable audits review historical financial criterion preparation information respect greenhouse gas presentation specify nonfinancial emission international standard information accordance suitable assurance engagement isae assurance criterion responsibility include adequate engagement greenhouse gas statement record keeping design issue international auditing implementation maintenance internal assurance standard board standard control system determine necessary require plan perform procedure enable preparation specify obtain limited assurance nonfinancial information free specify nonfinancial information prepare material misstatement fraud material aspect accordance error suitable criterion independence quality control base risk materiality consideration independent roche holding ltd perform procedure obtain sufficient accordance international code appropriate assurance evidence procedure ethic professional accountant include select depend assurance practitioner international independence standard issue judgement limited assurance engagement international ethic standard board isae revise substantially accountant iesba code fulfil scope reasonable assurance engagement ethical responsibility accordance relation risk assessment procedure iesba code found fundamental include understand internal control principle integrity objectivity professional procedure perform response competence care confidentiality assess risk consequently nature time professional behaviour extent procedure gather sufficient appropriate evidence deliberately limited review principle roche relative reasonable assurance engagement materiality process provide definition assurance obtain development adherence gris limited assurance engagement environmental social economic reporting reasonable assurance engagement requirement address soundness identification process determination perform follow assurance procedure impact stakeholder peer competition review integration relevant regulatory eview application roche group requirement integration key organisational guideline value objective report prioritisation review application roche group material aspect nonfinancial reporting contribution inspect integration sustainability guideline risk opportunitie group risk ite visit management inquiry management process adherence remotely visit select pharmaceutical suitable criterion diagnostic site usa china ssessment process data taiwan selection base consolidation quantitative qualitative criterion review management nonfinancial interview personnel responsible internal reporting process people nonfinancial report datum collection contribution key figure site visit group level assess aggregation process datum determine understand application group level roche nonfinancial contribution guideline believe evidence obtain ssessment key figure sufficient appropriate provide basis perform test sample basis evidence conclusion support select contribution people key figure roche accident conclusion rate energy consumption emission base procedure perform air water usage discharge number evidence obtain come employee fulltime equivalent percentage attention cause believe woman total workforce concern material respect relate completeness accuracy adequacy specify nonfinancial information consistency report roche holding ltd year end eview documentation analysis december follow apply relevant policy principle materiality determination process group review relevant documentation sample level disclose page basis include roche group nonfinancial report comply principle report policy management report gri standard structure documentation pricewaterhousecoopers birchstrasse postfach zurich telephone telefax wwwpwcch pricewaterhousecoopers member global pricewaterhousecooper network firm separate independent legal entityindependent limited assurance report roche design sustainability risk corporate governance sustainability opportunitie determination process group committee roche holding ltd work level inconsistent information report disclose paragraph risk management report pricewaterhousecoopers specify nonfinancial information mention subject matter section publish report roche holding ltd correct accordance suitable criterion christophe bourgoin annina binder restriction use purpose report zurich february report prepare corporate governance sustainability committee roche holding ltd solely purpose reporting specify nonfinancial information report purpose give conclusion accept assume responsibility legal accept liability connection purpose report include conclusion person report show hand come person shall entitle rely conclusion permit disclosure report combination suitable criterion enable corporate governance maintenance integrity roche hold ltds sustainability committee roche holding ltd website content responsibility demonstrate discharge corporate governance sustainability committee governance responsibility commission work carry assurance provider independent assurance report specify involve consideration maintenance nonfinancial information assume integrity roche hold ltds website accordingly accept responsibility liability assurance provider accept responsibility party full extent change occur specify permit law accept assume nonfinancial information suitable criterion responsibility initially present website publish hoffmannla roche ltd group communications basel switzerland tel wwwrochecom key date orderdownload publication internet wwwrochecompublication annual general meeting email baselwarehouseservicesrochecom march fax firstquarter sale medium relation april tel email mediarelationsrochecom halfyear results july investor relation tel ninemonth sale email investorrelationsrochecom october corporate sustainability committee tel email corporatesustainabilityrochecomimprint roche cautionary statement forward trademark legally protect look statement annual report contain certain forwardlooke link thirdparty page provide statement forwardlooke statement convenience express opinion identify word believe expect content thirdparty page expressly anticipate project intend seek disclaim liability thirdparty information estimate future similar expression use thereof discussion thing strategy goal plan intention factor cause roche annual report publish german actual result differ materially future english reflect forwardlooke statement contain annual report pricing reporting consist actual annual report product initiative competitor legislative finance report contain regulatory development economic annual financial statement consolidate condition delay inability obtain financial statement regard content regulatory approval bring product market management report article fluctuation currency exchange rate incorporation consist aforementioned general financial market condition uncertainty report exception remuneration discovery development marketing new report product new use exist product include limitation negative result clinical trial print nonchlorine bleach research project unexpected effect fsccertifie paper pipeline market product increase government pricing pressure interruption production loss inability obtain adequate protection intellectual property right litigation loss key executive employee adverse publicity news coverage statement earning share growth profit forecast interpret mean roche earning earning share subsequent period necessarily match exceed historical publish earning earning share rochef hoffmannla roche ltd basel switzerland trademark legally protect wwwrochecom